Development of a Gallium-Containing One-Bead One-Compound Peptide Library for the Discovery of New Molecular Imaging Probes by Bononi, Fernanda C
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
8-8-2014 12:00 AM 
Development of a Gallium-Containing One-Bead One-Compound 
Peptide Library for the Discovery of New Molecular Imaging 
Probes 
Fernanda C. Bononi 
The University of Western Ontario 
Supervisor 
Leonard G Luyt 
The University of Western Ontario 
Graduate Program in Chemistry 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Fernanda C. Bononi 2014 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Medicinal-Pharmaceutical Chemistry Commons, Organic Chemistry Commons, and the 
Radiochemistry Commons 
Recommended Citation 
Bononi, Fernanda C., "Development of a Gallium-Containing One-Bead One-Compound Peptide Library for 
the Discovery of New Molecular Imaging Probes" (2014). Electronic Thesis and Dissertation Repository. 
2194. 
https://ir.lib.uwo.ca/etd/2194 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
Development of a Gallium-Containing One-Bead 
One-Compound Peptide Library for the Discovery 
of New Molecular Imaging Probes 
(Thesis format:  Monograph) 
 
by 
Fernanda C Bononi 
 
Graduate Program in Chemistry (Molecular Imaging) 
A thesis submitted in partial fulfillment  
of the requirements for the degree of  
Master of Science 
 
The School of Graduate and Postdoctoral Studies 
Western University 
London, Ontario, Canada 
 
 
© Fernanda C Bononi 2014 
 ii 
 
Abstract 
 
An eight amino acid one-bead one-compound (OBOC) peptide library, containing a 
gallium-DOTA complex, was developed in an attempt to overcome common issues 
associated with the later addition of radionuclides to peptide chains of imaging probes. The 
further addition of a radionuclide often changes the binding properties of a peptide, as it adds 
bulk, and possibly charges. MALDI (matrix-assisted laser desorption ionization) tandem 
mass spectrometry was determined to be the method of choice in order to deconvolute 
gallium-containing peptide sequences. The library obtained was screened against the breast 
cancer cell lines MDA-MB-231 and MCF-7. Positive beads were isolated and sequences 
were determined before ligand validation, which included synthesis of peptides and further 
testing for binding affinity and specificity. Furthermore, positive peptides obtained through 
screening were developed into potential imaging agents by radiolabelling with 68Ga. 
 
Keywords: Molecular Imaging, OBOC library, gallium, MALDI, DOTA, peptide 
fragmentation 
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1 Chapter 1:  Introduction 
 
1.1 Molecular Imaging 
Molecular imaging can be defined as the real-time non-invasive visualization, 
characterization and evaluation of specific biological processes at the cellular and sub-
cellular level in an organism.1,2 By combining different areas of expertise, such as cell 
and molecular biology, chemistry, physics, mathematics, bioinformatics and medicine, 
we can obtain data that helps the understanding of the physiology and mechanisms of 
disease.1,2,3 Since molecular imaging looks for more specific molecular events than 
simple differentiation between diseased and healthy tissues, it has the potential to provide 
insight not only in early detection of diseases, but also in their physiology, progression 
and response to therapy.2 Besides their recent advent, molecular imaging modalities are 
showing promising results in early detection, differentiation and therapy response for a 
variety of diseases, including cancer. 
There are a number of different molecular imaging modalities, which are often 
combined to provide detailed information about the presence, the development and the 
prognosis of a disease.4 Some examples are MRI (magnetic resonance imaging), PET 
(positron emission tomography) and SPECT (single photon emission computed 
tomography). While MRI relies only on energy-tissue interactions using magnetism to 
produce images, PET and SPECT require the administration of agents or reporting probes 
containing a radionuclide.4 
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Table 1.1 Characteristics of imaging modalities PET, SPECT and MRI.5 
 
PET and SPECT have been broadly used for the past few decades for diagnosis and 
therapeutic evaluation of diseases as they offer the sensitivity required to monitor drug 
distribution, pharmacokinetics and pharmacodynamics.4 While both techniques rely on 
the use of radionuclides and the detection of emitted radiation, differences exist in the 
way that the radiation is detected. SPECT imaging detects gamma ray radiation emitted 
directly from radionuclides, and the image formed is a result of the radiation data 
collected by a gamma camera. The most commonly used radioisotope, 99mTc, is a well 
known gamma emitter; it has ideal nuclear properties and can be easily obtained from 
commercial generators.6 Its 6 h half-life allows for its preparation, hospital distribution, 
administration, accumulation time in the target tissue, and image collection, while 
reducing patient exposure to large doses of radiation.6 
PET, on the other hand relies on positron emitting radionuclides like 15O, 13N, 18F, 
and, more recently, 68Ga, 124I, 64Cu. As the radioisotope undergoes decay, it emits a 
positron that travels a short distance before interacting with an electron, thereby resulting 
in an annihilation event. The encounter produces a pair of 511 keV gamma photons that 
Imaging 
Modality 
Spatial 
Resolution 
 
Sensitivity  
(mole L-1) 
Amount of molecular 
probe used 
MRI 25-100 µm 10-3 to 10-5 Micrograms to Miligrams 
PET 1-2 mm 10-11 to 10-12 Nanograms 
SPECT 1-2 mm 10-10 to 10-11 Nanograms 
3 
 
travel opposite to one another (180o). Both photons are detected and the information 
obtained is used to create an image via mathematical reconstruction procedures of 
“coincidences” registered by the photon detectors.7 Isotopes used in PET imaging can be 
either cyclotron-produced, such as 18F, or generator-produced, such as 68Ga. Although 
both techniques offer limitless depth of penetration, PET offers advantages over SPECT, 
including improved sensitivity, and the ability to detect and record a higher percentage of 
emitted events. These advantages are due to the absence of a collimator and the use of the 
coincidence-detection method. This improvement in sensitivity can lead to better image 
resolution, improved temporal resolution, and the possibility of performing shorter 
scans.8 
Because of the difference in radionuclides used in PET and SPECT imaging, the 
discovery of suitable radiopharmaceutical probes is required for their use in the 
successful diagnosis and treatment of a specific disease. Despite the aforementioned 
advantages in using PET over SPECT, SPECT agents are often capable of providing 
more specific targeting, making SPECT the preferred modality for a variety of 
applications within biological organisms.8 As a result, the application of radionuclide-
based imaging techniques for disease diagnosis or treatment will depend on factors such 
as the discovery of suitable probes, the equipment available and the availability of 
radionuclides. 
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1.2 PET and SPECT Imaging Agents 
Some of the characteristics that are important for molecular imaging agents are 
high selectivity for the target or process of interest, a good ratio of specific over non-
specific binding, a good safety profile, good in vivo stability, time and cost-effective 
synthesis, and signal amplification.3 
Imaging agents can be of two different classes: targeted and non-targeted. Non-
targeted agents rely on general chemical properties, such as size, charge and lipophilicity, 
to determine their movement within the body.6 On the other hand, targeted agents utilize 
a targeting entity to drive the agent to the target of interest. 
18FDG (2-[I8F]-fluoro-2-deoxy-D-glucose) (Figure 1.1) is the most well known 
targeted agent currently in use. It is a glucose analog known for causing significant 
inhibition of glycolysis in ascites tumour cells grown in vitro.9 This probe is taken up by 
high-glucose-using cells, which are capable of internalizing it, but cannot undergo 
glycolysis, resulting in the probe being trapped in the intracellular environment as 2-[I8F]-
fluoro-2-deoxy-D-glucose-6-phosphate (FDG-6-P).10 
The tracer is able to measure the status of a malignant lesion; however, it only 
distinguishes between metabolically active cells and less active cells. Tumour tissue is 
nonhomogeneous; clusters of normal cells exist simultaneously with malignant or 
premalignant cells. As a consequence, the use of FDG does not reflect the real metabolic 
status of the malignancy. In addition, macrophages also demonstrate FDG uptake, as their 
activity increases in response to inflammation or after tumor therapy, thereby producing 
misleading imaging results.10,11 
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Figure 1.1 18FDG (2-[18F]-fluoro-2-deoxy-D-glucose), a widely used analogue of 
glucose for imaging tumours due to high sugar uptake. 
 
Targeted imaging agents are composed of an imaging entity, and a targeting entity, 
which is responsible for the biodistribution of the agent throughout the body. These two 
portions may be separated by a linker, which is used to add distance between the two 
entities, resulting in a better receptor-ligand binding (Figure 1.2).6  
 
 
 
Figure 1.2 The general scheme of a targeted imaging agent: a targeting entity, 
responsible for driving the agent to the site of action and interacting with the receptor; an 
imaging entity, responsible for emitting detectable radiation; and a linker, which is 
sometimes present to reduce interference between the two portions of the imaging agent. 
 
The radionuclide used as the imaging entity must have a half-life suitable for 
emitting enough detectable radiation within a reasonable time frame without exposing the 
patient to unsafe doses of radiation. In addition, its half-life must be long enough that it 
O
OH
HO
HO
18F OH
6 
 
can be synthesized, incorporated into a probe, transported, and injected into the body 
without significant decay. A variety of radionuclides are currently being employed in the 
different imaging modalities; however, applications with 68Ga are becoming more 
popular due to the availability of the radionuclide and its outstanding properties.  
Different radionuclides are attached to targeting entities differently: 18F and 11C, for 
example, can be integrated directly into the structure of an imaging agent, while 64Cu, 
99mTc and 68Ga require the presence of a chelator to incorporate the radionuclide into the 
imaging agent. 
The targeting entity is the vehicle that directs the imaging entity to the target or 
tissue of interest.7 It must have the ability to move through the body rapidly, avoid 
normal tissue uptake, and only interact with the target of interest, which results in 
improved performance and reduces any possible side effects of radiation exposure to the 
patient. Additionally, it should not produce an immune response, and must also be readily 
cleared from the body after imaging, ultimately leading to minimal patient exposure to 
radiation. 
The targeting entity is the variable part of targeted imaging agents, and can be 
modified in order to increase affinity or specificity to the target of interest. Thus, the 
development of new molecular imaging agents is dependent on the discovery and further 
development of new targeting entities. 
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Table 1.2 Radionuclides used for SPECT imaging.5 
 
 
 
Table 1.3 Radionuclides used for PET imaging.5 
 
 
 
 
Nuclide Half-life (h) Type of emission Principal 
photon emission 
energies (MeV) 
123I 13.2 Electron capture 0.16 
99mTc 6 Isomeric transition 0.14 
111In 67.9 Electron capture 0.17/0.25 
67Ga 78.3 Electron capture 0.09/0.19/0.30 
201Tl 73.1 Electron capture 0.17 
Nuclide Half-life (min) Type of emission Maximum energy 
(Mev) 
11C 20.3 β+ 0.97 
13N 10 β+ 1.20 
15O 2 β+ 1.74 
18F 110 β+ 0.64 
64Cu 76.2 β+/electron capture 0.66 
68Ga 68.1 β+/electron capture 1.90 
76Br 972 β+/electron capture 4.00 
124I 60192 β+/electron capture 2.14 
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1.3 68Ga as an Imaging Entity  
68Ga, a generator-produced radionuclide, has a half-life of approximately 68 
minutes, which makes it possible for it to be synthesized, incorporated into an imaging 
agent, and applied for posterior injection and detection of the radiation emitted using PET 
imaging. 
68Ga is becoming a PET radioisotope of interest for reasons related to its convenient 
half-life of 68 minutes, economical viability and its accessibility from a 68Ge/68Ga 
generator.12 This radionuclide decays to the stable daughter isotope, 68Zn, by positron 
emission (89%) and electron capture (11%) with a maximum positron energy of 1899 
keV.13,14 
Within the past few years, the number of references to 68Ga-labeled analogues for 
PET imaging has increased substantitally,15,16 and recent studies show that peptides 
labeled with 68Ga are able to provide better images than analogues labeled with other 
radionuclides, such as 111In.17,18 To date, 68Ga has been used to image a variety of 
ailments, including tumours17, bone metastasis19, and infections.20,21 A bifunctional 
chelator, which contains a portion for attachment to a molecule or peptide and a portion 
responsible for chelating gallium, is attached to a targeting entity in order for the 
radionuclide to be incorporated into the imaging agent’s structure. 
A 68Ge/68Ga generator is composed of a column containing a stationary phase on 
which 68Ge, the parent isotope, is absorbed. A solution of EDTA 
(ethylenediaminetetraacetate) or HCl, in the newer generators, is used to elute the 
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radionuclide.  The shelf life of such a generator is one to two years, and it can be used up 
to three times a day.7 
The chelation chemistry of 68Ga is well understood, as its prevalent state in aqueous 
solution is +3, and at higher pH, it has the propensity to demetallate from its complexes, 
forming insoluble Ga(OH)3 in the absence of stabilizing ligands, and at physiological pH, 
forms a gallate anion, Ga(OH)4-.6,22 Gallium is classified as a hard Lewis acid due to its 
high charge density and small ionic radius, and, therefore, it binds strongly to ligands that 
are hard Lewis bases, such as nitrogen and oxygen atoms.23 Its small ionic radius (0.62 
Å) allows it to be six-coordinate in a distorted octahedral geometry24, and  complexes that 
have spare coordination sites are more sensitive to hydrolysis.6 
As mentioned previously, polydentate ligands with hard donor groups are the most 
common class of chelators for 68Ga. Common chelators include DTPA 
(diethylenetriaminepentaacetic acid), NOTA (1,4,7-triazacyclononane-1,4,7-triacetic 
acid) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid); the number 
of labeled molecules using these chelators has increased over the past few years (Figure 
1.3). 
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Figure 1.3 Schematic representation of bifunctional chelators DTPA, NOTA and 
DOTA. 
 
1.4 Peptides as Targeting Entities 
There are a variety of compounds that can be used as targeting entities: small 
molecules, peptides, monoclonal antibodies (mAb) or mAb fragments.7 
Small molecules have a lower molecular weight when compared to antibodies and 
peptides, which allows them to move through the body and access major targets more 
easily, as well as increases their resistance to enzymatic degradation. The affinity of a 
targeted imaging agent for a biological target of interest should be unchanged or very 
close to that of the targeting entity alone after radiometal labeling; however, this is rarely 
the case when small molecules (MW<1000) are incorporated into the structure of an 
imaging agent, as the imaging entity corresponds to a considerable part of the probe size 
and weight. 
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Antibodies have the advantage of having extremely high affinity and specificity to 
targets and also being very stable to degradation. Monoclonal antibodies, such as 
trastuzumab, have been approved for clinical use25; however, their large molecular 
weights (usually over 100 kDa) prevent them from being able to cross biological barriers 
and can lead to problems related to immunogenicity26, which is the result of their being 
easily recognized by the immune system, taken up by the reticuloendothelial system 
(RES)27, the latter of which can also cause a number of undesired side effects.28 
Peptides present a number of important advantages over other molecules. Their 
favourable pharmacokinetics29, high receptor binding affinity and selectivity30, and the 
lack of side effects31 make peptides an attractive class of molecules for the design of new 
imaging probes. 
In addition to promising biological characteristics, the chemistry of peptides is very 
compelling. The process of synthesizing peptides is straightforward, radiolabeling is 
easily performed, especially when bifunctional chelators are utilized, as they possess a 
well-established chelation chemistry and can be easily incorporated into the peptide 
structure.32 Peptides are stable to the chemical modifications that are associated with the 
addition of radionuclides, including elevated experimental temperatures and the use of 
organic solvents. In addition, peptides can be easily modified to avoid rapid enzymatic 
degradation30 through the use of natural and unnatural amino acids, and D-amino acids, 
all of which can be used to alter the chain length and properties. 
Peptide-based imaging agents were introduced into the clinic more than two 
decades ago.33,34 Specifically, the somatostatin (SST) analog 111In-DTPA0-octreotide 
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(111In-OctreoScan or 111In-pentetrotide) is an agent that effectively images SST receptor-
positive lesions such as neuroendocrine tumours (NETs) and small cell lung cancer 
(Figure 1.4).35,36,37  
Following the advent of 111In-DTPA0-octreotide, peptide imaging agents were 
further developed to include analogs of neurotensin38, exendin39 and new analogs for SST 
receptors, such as DOTATOC, which binds to the human somatostatin receptor subtype 2 
(hSSTr2), which has been shown to be highly expressed in various human tumours.40 
 
 
 
 
 
 
 
 
Figure 1.4 111In-DTPA0-octreotide. A peptide based imaging agent that acts on the 
somatostatin receptor. The probe contains a D-Phe and D-Trp, is cyclized via a disulfide 
bond between the two cysteine residues and contains 111In-DTPA 
(diethylenetriaminepentacetic acid) as the imaging entity. 
 
DOTATOC was initially developed for labeling with 90Y or 177Lu, and was used for 
targeted radiotherapy40; however, it has more recently been studied as a potential PET 
agent when chelated with 68Ga (Figure 1.5) because it shows promising results in the 
diagnosis of NETs when compared to conventional detection methods.17,41 
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The advantages in the synthesis of peptides and the ease of incorporating them into 
an imaging entity has resulted in their becoming important molecules in the development 
of novel molecular imaging agents. 
 
 
 
 
Figure 1.5 68Ga-DOTATOC, a somatostatin analog that is showing promising 
results in the diagnosis of neuroendocrine tumours (NETs). 
 
1.5 Discovery and Development of Peptide-based Imaging Agents 
The strategy for design and synthesis of new imaging probes is similar to the 
process of generating drug-like molecules. Probes are expected to show high affinity and 
selectivity for the target receptor or organ of interest. As a result, small amounts of the 
radioactive probe are required to generate precise and well-defined images of the 
receptor.5 
The discovery of new peptide-based imaging probes is accomplished by two 
different methods: a rational approach, in which standard peptide chemistry is carried out 
to determine the regions critical for receptor binding affinity of an endogenous peptide 
that is known to interact with the desired target, and a combinatorial approach, in which a 
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large number of compounds are screened against a particular target to determine which 
ligands show the most promising results. 
Rational design is a broadly used method for drug discovery, and more recently, 
has been applied for the discovery of imaging agents. The first step in rational design is 
to identify a molecular target of relevance for a particular disease, and subsequently to 
identify a lead peptide, which can be of natural or synthetic origin. Endogenous peptides 
are prone to quick degradation, and, therefore, are normally not useful imaging agents. 
However, endogenous peptides can be modified into more stable agents while 
maintaining high selectivity and binding affinity by the incorporation of D-amino acids or 
unnatural amino acids. Furthermore, more hydrophilic and lipophilic amino acids, as well 
as charged amino acids can be added to change the properties of the peptide. 
Despite the advantages of rational design, it is limited by the fact that it depends on 
information available on the target of interest and the endogenous ligand, which are not 
always readily available. General methods to obtain such information can be time 
consuming; for example, crystallization leads to limited or no information on certain 
targets. Because of these limitations, other design methods have been developed and are 
now currently in use. 
Peptide libraries generally overcome the limitations of rational design, as 
information about the target of interest or endogenous ligand is not required. With 
peptide libraries, a large number of peptide sequences are simultaneously tested against a 
cell line or receptor for binding affinity. The sequences showing high affinity to the target 
can then be identified, and further modifications can lead to the development of new 
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imaging agents. This approach is less time consuming and more economical than rational 
design, as a large number of potential imaging agents can be discovered and developed 
simultaneously. The use of automated synthesizers and the development of more efficient 
ways of screening such compounds have popularized this approach in the past few 
decades.  
The first big advancement in the development of peptide libraries was in the early 
1990s when Furka et al.42 presented a method for the simultaneous synthesis of a mixture 
of 27 tetrapeptides and that of 180 pentapeptides. This new synthetic method laid the 
foundation for the development of some types of peptide libraries available today. 
There currently exist a variety of methods for developing random peptide libraries, 
and subsequently obtaining the sequences of peptides that show affinity for a particular 
target of interest. For example, the SPOT-synthesis technique and light directed-chemical 
synthesis are methods in which the sequence of the peptides is known based on physical 
location. On the other hand, phage display and one-bead one-compound (OBOC) 
libraries are completely random, requiring the use of other techniques to determine the 
sequences of the positive peptides or “hits” obtained through screening against a target of 
interest. 
SPOT libraries were first presented in 1990 by Frank et al.43; this type of library is 
designed to synthesize hundred or thousands of peptides arranged on a planar cellulose 
support. The chemical reaction occurs on little spots, corresponding to where droplets of 
the reagents are added. The peptide is subsequently attached to the cellulose support by a 
method that is similar to standard solid phase peptide synthesis. The surface holds a large 
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number of spots, or a large number of peptide sequences, which can be identified by their 
location on the support. The size of the spot reflects the concentration of the peptide 
(Figure 1.6).44 
 
 
 
 
 
Figure 1.6 A cartoon representing the principle of SPOT libraries. Adapted from 
Frank et al. (2002).44 
 
Light-directed parallel chemical synthesis combines tools from solid phase 
peptide chemistry, photolabile protective groups, and photolithography for the synthesis 
of a peptide library.45 The precision of the methodology allows for the synthesis of 
thousands of compounds to be retained in highly compact matrices. The immobilized 
compounds are incubated with the molecular binding agent of interest. Negative and 
positive binding events are then recorded, and sequences are determined based on their 
location. 
The major limitation of these two methods is the limited number of peptide 
sequences that can be screened at any given time. Even when the processes are 
automated, the two methods described result in a maximum of an one hundred thousand 
peptide sequences.44 For drug or imaging agent discovery, by screening a larger number 
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of compounds, it increases the possibility of obtaining positive results. As a result, there 
is a need for new methods for designing libraries, in which random sequences are used, 
requiring further experiments to determine the sequences of the positive peptides 
obtained by screening. 
Of all of the types of combinatorial peptide libraries, phage display and one-bead 
one-compound (OBOC) libraries are two techniques that provide the possibility of 
screening a larger number of peptide sequences, potentially numbering in the millions. 
Phage display libraries utilize standard recombinant DNA technology to engineer 
phage for specific peptide sequences with DNA coding, and combinations of different 
codon sequences are then cloned into phage libraries. After infection of E. coli cells with 
phage, the peptide sequences are synthesized as a coat protein for the phage.46 To screen 
these libraries, the receptor is bound to a solid support, and the mixture containing all 
phages is passed over the immobilized receptor. Phages containing peptide sequences that 
show affinity to the receptor are retained on the surface while the unbound ones are 
washed away. The addition of a solution that removes the receptor-peptide bonds results 
in the collection of the positive phages in an “enriched” solution, which contains only 
phages that show some affinity to the receptor in question. The positive phages are still 
able to infect fresh bacterial host cells, leading to an amplified eluate, which is used for 
other rounds of affinity selection. After the final screening, the positive phages in the 
eluate are propagated and characterized individually. The positive sequences are then 
determined by ascertaining the corresponding coding sequence in the viral DNA.46 
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A phage display library has the potential to display billions of peptide sequences, 
and subsequent DNA sequencing identifies bioactive peptides.  This type of library is 
accessible commercially, and peptide sequences can be readily obtained. However, 
despite their ability to contain unnatural amino acids47,48, phage display libraries are 
limited by their inability to contain non-peptide structures, as sequencing methods cannot 
account for these structures. OBOC libraries, on the other hand, are not biological in 
nature, which permits them to easily incorporate D-amino acids, unnatural amino acids, 
as well as non-peptide structures. Even though OBOC libraries are usually smaller than 
phage display libraries, they allow thousands to millions of compounds to be synthesized 
in a short period of time.49 
 
1.6 One-Bead One-Compound Peptide Libraries 
Described in 1991, the one-bead one-compound (OBOC) combinatorial method 
allows for the synthesis and screening of thousands of compounds against a variety of 
targets in a short period of time using on-bead binding assays.49 Using TentaGel as a 
solid support, the first OBOC study described a library synthesis using the “split-mix” 
methodology (Figure 1.7), which consists of having a specific number of peptide vessels 
corresponding to the number of amino acids to be used in the random sequences, and 
subsequently mixing and splitting the contents of the vessels again at the end of each 
coupling cycle. This allows for the creation of a library of compounds, where each 
individual 90 µm bead displays up to 1013 copies of one chemical entity.49,50  
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OBOC libraries benefit from being able to contain unnatural amino acids, D-amino 
acids, and non-peptide structures, and are therefore, suitable for drug or imaging agent 
development, as peptides containing unnatural amino acids are generally more resistant to 
proteolysis.51 
While initially developed to screen libraries consisting of short linear peptide 
sequences, this methodology has more recently been used to develop cyclic peptides52, 
peptidomimetic and small molecule libraries.53 In addition, it has been successfully used 
in many high-throughput screening assays to identify protein kinase and protease 
substrates and inhibitors54-57, G-coupled protein receptor inhibitors53, ligands against 
mRNA precursors58, and integrin-specific peptides against breast cancer cells51,  among 
others. 
The main steps in OBOC methodology are synthesis, screening, and sequence 
deconvolution of peptide beads. Subsequent ligand validation is the key step that follows 
sequence determination of positive “hits”, as it leads to the synthesis and characterization 
of the discovered ligands prior to further biological evaluation for target affinity. 
Although revolutionary in its concept, improvements to the synthesis and screening 
of such libraries have been made throughout the years, resulting in different design 
approaches being incorporated according to the needs of particular studies. 
In order to make it possible to screen the same beads against different targets, the 
concept of “rainbow beads” was developed, which allows for the possibility of screening 
different libraries simultaneously by encoding each library with a different colour.59 A 
similar concept was explored when a method to immobilize beads in a gel support was 
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reported. It allowed for the screening of an entire library sequentially many times with a 
series of distinct probes. 60,61 
 
 
 
 
 
Figure 1.7 The synthesis of OBOC peptide libraries, where A-H are amino acids 
and using two “split-mix” steps.  The number of possible peptide sequences will increase 
exponentially in each step following N = aax, where N is the number of sequences, aa is 
the number of amino acids in a peptide, and x is the number of amino acids available for 
each step. 
 
The screening process, which involves the selection of positive beads for further 
identification, was initially performed manually using a confocal microscope and a 
pipette. Recent studies attempted to automatize the screening process by using cells that 
express a fluorescent protein and a Complex Object Parametric Analyzer and Sorter 
(COPAS) platform, which sorts beads based on the fluorescence of the cells. More 
recently, Cho et al.27 reported the development of a screening method that combined 
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fluorescence and magnetic field for the purpose of bead separation. Separation 
procedures with two different steps may decrease the number of false positives normally 
encountered with beads sorting through the COPAS platform. 
 
1.7 Sequence Deconvolution and Identification of Peptide Sequences 
The first synthesized OBOC library contained 19 natural amino acids, excluding 
cysteine due to the potential of disulfide bond formation, and the sequences of positive 
beads were determined by automated Edman degradation49, which has been the method 
of choice since the advent of OBOC libraries.  In this method, each amino acid is 
converted to its phenylthiohydantoin (PTH) derivative, from N-terminus to C-terminus. 
The formed PTH amino acids are identified based on their retention times by reversed-
phase high-performance liquid chromatography (RP-HPLC) and compared with reference 
standards for all 20 natural amino acids.62 
 
Scheme 1.1 A schematic of Edman degradation using phenylisothiocyanate to form 
a phenylthiohydantoin derivative of the N-terminus amino acid residue. R represents the 
side chains of amino acids. 
 
Liu et al.62 reported the use of Edman microsequencing to identify unnatural 
amino acids within a peptide structure. They were able to trace the elution profile of 19 
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out of 35 unnatural amino acids, which can be readily distinguished from the 20 natural 
amino acids on a modified elution gradient. 
Although useful for peptide sequencing, this technique is limited when used for 
applications related to non-peptide structures and N-capped peptides. The reaction with 
phenylisothiocyanate does not occur, and it is not possible to identify these structures. In 
addition, the high cost per sample and time-consuming procedure make it challenging to 
sequence multiple samples.63 
Matrix-assisted laser desorption ionization (MALDI) tandem mass spectrometry 
for peptide deconvolution was first described by Youngquist et al.64. It used capped 
deletions in order to encode a combinatorial library and simplify the sequencing process. 
This method not only revealed a rapid method for sequencing, but it also allowed a direct 
assessment of the quality of the synthetic library in question, as side-reaction products, 
incomplete products, and deletion peptides could be observed.64 
Few studies had since been developed to show the usefulness of this methodology 
until Amadei et al.63 established a fast, economical, reliable, and reproducible method for 
structure determination of small peptides without the need for further complex 
experiments. This study used only the MALDI tandem time-of-flight mass spectrometry 
(MALDI TOF/TOF MS) instrument to photocleave, desorb, ionize and fragment ‘on-
bead’ peptides. A related report by Semmler et al. also describes the use of a 
photocleavable library and sequencing using MALDI.65 In this report, the peptide 
sequence is determined by a two-step process; the peptide is first cleaved off of the resin, 
and is then analyzed by MALDI tandem mass spectrometry. Thus, the focus of recent 
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studies is to optimize the process of removing the peptide from resin and subsequently 
submitting the sample for analysis, in order to make it a high-throughput methodology. 
 
1.8 [Ga]DOTA Peptide Libraries 
The discovery of peptide-based targeted imaging agents is often difficult due to the 
required addition of a radionuclide to a peptide. When either rational design or random 
library approach is used, the addition of an imaging entity, consisting of a radionuclide, a 
chelator, and a linker, results in modifications to the binding properties of the original 
peptide, as it adds bulk and possible charges. This is even the case with the discovery of 
agents that present high affinity for a particular target. For small peptides (<2000 Da), for 
example, the imaging entity corresponds to a significant portion of the mass and size of 
an imaging agent, suggesting that the changes to the binding properties are more 
perceptible; however, studies have shown that even larger peptides, where the imaging 
entity mass and size corresponds to a smaller portion of the probe, can be influenced by 
the addition of the imaging entity. 
After the addition of the imaging entity, the peptide structure is modified in order to 
create a compound with more affinity and specificity to the target of choice. This step is 
often an inefficient process, particularly when peptide sequences are discovered using a 
random library approach such as OBOC, where information of how the peptide binds to 
its target, its conformation, and bond distance are not available. 
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Recent advances in the synthesis and screening of OBOC libraries, and the ability 
to incorporate non-peptide structures, suggest that the addition of an imaging entity to a 
peptide library prior to screening has the potential to overcome the current limitations of 
OBOC, as it will account for changes in binding affinity before the screening. Thus, only 
those sequences that show affinity with the radionuclide present will be further analyzed 
and characterized. 
As mentioned previously, 68Ga is becoming a relevant isotope for diagnostic 
purposes. The incorporation of 68Ga is achieved with bifunctional chelators; the most 
widely used functional chelator for 68Ga is DOTA.66  
More recently, DOTA labeled with 68Ga has been added to a variety of peptides to 
be used against a variety of targets. For example, Octreotide, a metabolic stable SST 
derivative, was conjugated with DOTA and labeled with 68Ga for imaging of beta cell 
mass in diabetes mellitus (DM) model rats showing pancreatic accumulation, which was 
found to be significantly reduced in normal animals and animals that had excess amounts 
of unlabeled Octreotide administered previously67. 
The design of a [Ga]DOTA peptide library will lead to a more efficient discovery 
and development of new peptide-based PET imaging tracers. Preliminary work is 
required to determine the feasibility of such a library, and to determine if synthesis, 
screening and sequence deconvolution can be performed when the bifunctional chelator 
and metal are present. 
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1.9 Thesis Rationale 
Gallium is becoming an isotope of relevance for PET oncological imaging, which 
fits our purpose for the synthesis of imaging-entity containing libraries. Although little is 
known about library screening of metal-containing libraries, the stability of the 
[Ga]DOTA complex in physiological conditions is already known to be satisfactory. 
Moreover, to date, there has been no report on either successful on-resin gallium 
coordination or the use of MALDI tandem mass spectrometry to determine the sequences 
of peptides containing gallium. 
Furthermore, the first step in exploring the utility of a [68Ga]DOTA peptide library 
involves the synthesis of a test peptide, which is coupled to DOTA, coordinated with 
69/71Ga and is then analyzed using MALDI tandem mass spectrometry, in order to 
determine how the presence of gallium, and its typical isotropic signature, will interfere 
with the fragmentation profile of peptides. 
Due to the limitations associated with Edman degradation and other types of 
sequencing methods, MALDI tandem mass spectrometry will be evaluated as a method 
of identifying peptide sequences that contain the [Ga]DOTA complex as it has the 
potential to be a more efficient way of obtaining the sequences of bioactive peptides. 
Lastly, with a reliable method to identify unknown peptide sequences, and a stable 
peptide library coordinated with gallium, the library will be tested against useful targets 
in order to validate the method. For this purpose, the [Ga]DOTA peptide library is 
screened against MDA-MB-231 and MCF-7 cells as a way of identifying those peptides 
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that bind specifically to one cell line, thereby allowing for the potential detection and 
monitoring of breast cancer. 
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2 Chapter 2: Synthesis, coordination and sequence 
deconvolution of a [Ga]DOTA-octapeptide 
 
2.1 Introduction 
Due to the properties of DOTA as a stable and well characterized chelator and  
gallium as a great imaging entity, the [Ga]DOTA complex is the imaging entity of choice 
for the development of an OBOC library. Furthermore, the patterns of fragmentation of 
[Ga]DOTA-containing peptides are analyzed utilizing MALDI tandem mass 
spectrometry, which is not only able to identify peptide sequences, but also show the 
presence of gallium and account for non-peptide structures.  
 
2.1.1 Peptide Synthesis 
Peptide synthesis consists in the coupling of amino acids protected with 
orthogonal protecting groups to a solid support. It was developed in an attempt to 
optimize the synthesis of long chain polypeptides, when solubility and purification of 
peptides become more challenging as the number of residues increases.68 
The general concept involved in solid phase peptide synthesis is the attachment of 
the first amino acid of the peptide chain to a solid polymer (resin) by a covalent bond. 
The subsequent amino acids are added in a stepwise manner until the desired sequence is 
obtained. The sequence is then removed from the support. 
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Having the peptide attached to an insoluble support allows for the proper washing 
and filtering of reagents and byproducts, leading to more pure intermediates without the 
use of time consuming techniques like recrystallization or chromatography. 
The support used for solid phase peptide synthesis has to be insoluble in all 
solvents used during the process, so that filtration can be easily performed. It contains an 
insoluble polystyrene cross-linked backbone where polyethylene glycol (PEG) groups are 
attached. It also has to contain functional groups, within the PEG groups, where the first 
protected amino acid can be linked by a covalent bond. The functional group present will 
depend on the type of resin used and the existence of methods to remove the peptide from 
the support after synthesis. 
The most common protecting group for the backbone amines is 
fluorenylmethyloxycarbonyl (Fmoc), a base-labile group that can be removed with the 
use of a piperidine solution in dimethylformamide (DMF). Side chains, on the other hand, 
are protected with acid-labile protecting groups. That way, selective deprotection of 
terminal amines and coupling of subsequent amino acids can be achieved. There are a 
variety of acid-labile protecting groups, with tert-butoxycarbonyl (Boc) being the most 
commonly used amine protective groups and tert-butyl (tBu) esters for carboxylic acids. 
The process of adding amino acids one by one to a solid support follows a 
procedure deprotection followed by coupling of amino acids. The resin contains a free 
amine that will react with the free carboxylate of an Fmoc-amino acid to form an amide 
bond. Since the carboxylate is the only portion of the amino acid not protected, there will 
be only one possible reaction. 
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The coupling reaction between amines, carboxylates and amide bonds is known to 
be slow, which leads to the need of coupling agents (Scheme 2.1). The first coupling 
reagents to be used were carbodiimide derivatives such as N,N'-dicyclohexylcarbodiimide 
(DCC) and N,N'-diisopropylcarbodiimide (DIC). These compounds react with the 
carboxyl group of amino acids to form a highly reactive O-acylisourea intermediate, 
which is quickly displaced by a nucleophilic attack from the deprotected amine at the N-
terminus of the growing sequence. However, besides the possibility of amino acid 
racemization, these reagents are also known to produce a reactive intermediate and a 
number of side reactions. Agents that required the addition of an activating base to 
mediate the coupling were then developed, such as (benzotriazol-1-
yloxy)tris(dimethylamino) prosphonium hexafluorophosphate (BOP), O-(Benzotriazol-1-
yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) and O-(6-
chlorobenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HCTU). 
The activating base most commonly used is diisopropylethylamine (DIPEA). 
 
 
 
 
Scheme 2.1 A diagram showing the steps of peptide synthesis: Fmoc deprotection using a 
20% piperidine solution in DMF, and amino acid coupling using HCTU and DIPEA. This 
cycle is repeated until the length of the peptide chain is reached. 
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The side chain protecting groups, which are acid labile, are removed by the 
addition of acids such as trifluoroacetic acid (TFA). The solution (cocktail) used to 
remove acid-labile groups contains a high percentage of acid and a small percentage of 
scavenging agents such as water, phenol and triisopropylsilane (TIS). The scavenging 
agents are responsible for removing the electrophiles produced from the cleavage of 
protecting groups by reacting with them. That way, reactions of these groups with the 
peptide chain are avoided. 
 
2.1.2 Ga Labeling using DOTA as a Chelator 
Due to its small cationic radius, Ga(III) is often six-coordinate in a distorted 
octahedral fashion.24 As a result, polydendate ligands with hard donor groups are the first 
choice for gallium labeled biomolecules. DOTA, a ligand based on polyaza-macrocycles, 
when in a Ga-DOTA complex, shows high thermodynamic stability, which makes it a 
good fit for clinical practice.6 In [Ga]DOTA-D-Phe-NH2, Ga(III) is coordinated by a 
N4O2 donor set while one carboxylic acid is deprotonated and does not coordinate to the 
metal. The remaining carboxylic group is conjugated with the amino acid via an amide 
bond.69 
DOTA-tris(tert-butyl ester) is a popular ligand for attaching DOTA to a peptide 
on solid support as it can be used to derivatize the N-terminus of a peptide chain attached 
to the solid support or a lysine side chain.70 
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2.1.3 OBOC Sequencing Methods 
Although conventional Edman degradation has been widely used for sequence 
determination of OBOC peptide libraries, due to its intrinsic limitations, new coding 
methods that enable the identification of unnatural and N-termini blocked elements have 
been developed. One of these strategies requires the addition of a “recognition arm”, a 
branched linker that is synthesized in parallel with an arm that encodes the recognition 
polymer’s sequence. The identity of this recognition polymer is determined by 
sequencing the coding arm.71,72 Although great in theory, the addition of a coding 
polymer adds extra steps to the library synthesis process and may also interfere with the 
screening against the target protein. 
In order to deal with these limitations, a variety of other sequencing methods have 
been proposed, including the addition of coding molecules to the interior of beads, while 
keeping the test compound on the exterior, which decreases or eliminates the interference 
of the coding molecule with the binding of the testing compound to the target.73 In this 
method, the synthetic step of both coding and testing compounds are combined, 
eliminating the extra steps present within the first strategy. The most efficient and reliable 
method for the modification of the bead surface consists on the use of a biphasic solvent 
environment, causing the surface of TentaGel beads to be exposed to organic solvent 
containing a derivatized reagent, such as Fmoc-Osu, while the interior of the bead 
remains in water, without any reagents.73 
The limitations of the former procedure led to a search for faster methods like the 
“ladder-sequencing” method.74 Here, the N-terminus of each bead-bound peptide was 
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partially degraded, generating a series of peptide “ladders”, which were later analyzed by 
mass spectrometry. The sequences can be determined by the mass difference between 
adjacent peaks, as it will account for the molecular weight of one amino acid.75 A similar 
method developed by Youngquist et al.76 utilizes the same concept, but by capping the N-
terminus portion of the peptides after each coupling cycle during the library synthesis, it 
can be also applied to small molecules and peptidomimetic libraries, a significant 
limitation of the previous method, which could only be applied to standard peptide 
libraries. 
Partial Edman degradation and mass spectrometry (PED-MS) is similar to the 
ladder-sequencing method, where an OBOC bead will contain a series of capped peptide 
sequences. The advantage here is that all capping is performed after library screening, 
reducing the interference with the binding of the testing peptide to its target. In this 
method, a resin-bound peptide is treated with a mixture of phenylisocyanate (PITC) and a 
small amount of a capping agent. Both the PITC and capping agent compete for reacting 
with the N-terminal amine of the peptide. After addition of the reagents, 90-95% of the 
peptide undergo cleavage, while 5-10% react with the capping agent in each step. 
Repetition of the PED reaction for as many cycles converts the original peptide into a 
series of sequence-related truncation products.77,78 By analyzing the peptide mixture 
using matrix assisted laser desorption ionization mass spectrometry (MALDI-MS), the 
sequence of the original peptide is obtained (Figure 2.1). The reliability of this method 
has been tested by obtaining the sequence of peptides from an OBOC library using Fmoc-
OSu as a capping agent.79 The major limitation of this method, however, is the 
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requirement that peptides have to contain free N-terminal amines, which is not ideal for 
libraries containing non-peptide structures or that went through N-terminal acetylation. 
 
 
 
 
Figure 2.1 The procedure for peptide sequencing by the use of ladder synthesis and 
partial Edman degradation and mass spectrometry. 
 
Tandem mass spectrometry (MS/MS) is an important technique that has proven to 
be valuable for sequence deconvolution of combinatorial libraries. It employs two stages 
of mass analysis, which makes it able to selectively examine the fragmentation of a 
particular ion or a mixture of ions. Here, a peptide is ionized, the ions formed are 
identified and separated based on their m/z ratio. The precursor ion is chosen based on 
the mass range of choice for further fragmentation, where information on the sequence of 
a peptide is obtained. The most commonly used methods for the soft ionization of 
peptides are ESI (electrospray ionization) and MALDI (matrix-assisted lased 
desorption/ionization).  
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The use of MALDI tandem mass spectrometry for the sequence determination of 
peptide libraries have been recently reported by different research groups80,81, and is 
becoming the sequencing method of choice, as it is a fast, reliable and economic method 
that is also able to identify non-peptide structures. 
In order to simplify the spectrum and help discern specific fragment series, some 
groups reported on the use of chemical derivatization, which consists of the addition of 
chemical labels, creating a mass shift or fragmentation pattern that helps to identify and 
differentiate fragment series. Examples of this technique are the introduction of amidine 
labels, creating a mass shift that is useful for protein identification82, and the introduction 
of halogenated mass-tags, either on topologically segregated bifunctional beads along 
with the bioactive sequence itself83, or directly to the N-terminus of a peptide84, 
facilitating the differentiation between different elements due to the unique isotope 
patterns associated with the halogen. 
The use of MALDI for sequence determination of a resin-bound molecule has 
been reported, where an ultraviolet (UV) MALDI laser was used to cleave the molecule 
off resin and to promote its gas phase ionization for subsequent analysis, making a one 
step process.85 The same results were achieved when using a 355-nm Nd:YAG laser in a 
MALDI-TOF/TOF (tandem time-of-flight) instrument, where peptide fragments were 
identified with a mass accuracy of 0.1 Da of expected values.63 
Besides the variety of sequencing methods for OBOC libraries that are currently 
available, with the addition of a chelator and a metal, there are a few limitations to most 
of these methods, as the N-terminus of the peptides is no longer a free amine, and also 
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due to the presence of non-peptide structures.  Overall, tandem mass spectrometry, using 
MALDI as the ionization method turned out to be the best fit for sequence investigation 
of a [Ga]DOTA-containing OBOC peptide library. 
 
2.1.4 Tandem Mass Spectrometry 
When a peptide is submitted to fragmentation, the bond breakage will mainly 
occur through the lowest energy pathways, which in the case of a peptide is through the 
amide bond. This leads to the two most common ions in tandem mass spectrometry: the b 
and y ions (Figure 2.2). Other fragments that may be found are a, c, x, z. In a, b and c 
fragments, the charge is retained by the amino terminal fragment, while for x, y and z, the 
charge is retained by the carboxy-terminal fragment (Figure 2.3).86  
  
 
 
 
 
Figure 2.2 A general peptide structure showing the bonds that are broken to form 
b and y ions, the most common ions visualized in tandem mass spectrometry. 
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The most important characteristic of peptide fragmentation is that the patterns of 
fragmentation will depend entirely on the sequence of the peptide, specifically, it will 
depend on the side chains of the amino acids involved. During the initial ionization, basic 
residues normally accept protons from the matrix, but upon excitation, using collision-
induced dissociation (CID) for example, the protons that are added to a peptide can 
migrate to various protonation sites before fragmentation. This means that one 
predominant structure will be present for peptide ions where the added proton is 
sequestered, and differently protonated forms will be present for easily fragmented 
species. This theory is known as the mobile proton theory, and is the most complete 
explanation of how peptide fragmentation occurs in tandem mass spectrometry.87 
 
 
 
 
 
 
 
 
 
Figure 2.3 Fragments in tandem mass spectrometry. In a, b and c fragments the 
charge is retained on the N-terminus of the peptide, while in x, y and z the charge is 
retained on the C-terminus. 
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In tandem mass spectrometry, the difficulty lies in the fact that information in a 
spectra in not always complete. The presence of intervening peaks or absence of peaks 
due to poor fragmentation will interfere on the ability to determine the sequence of 
peptides. In other words, proper fragmentation by mass spectrometry will solely depend 
on the ability of the peptides to produce a well defined series of peptide fragments, where 
the difference between two neighbouring peaks produced correspond to an individual 
amino acid. 
Although still an issue, with the use of databases, it is still possible to obtain 
enough information to match the data obtained from mass spectrometry uniquely to a 
peptide present in a database, based on the profiles of observed and expected ions. But 
when adding certain modifications to peptides, most of the time, information obtained 
from spectra cannot be matched with existent databases, as some modifications are not 
accounted for. However, the presence of certain isotopic labels in the N-terminus of 
peptide sequences can enhance the quality of the spectra obtained as it adds an isotopic 
signature to b ions, which can be easily differentiated, and sequences can be more easily 
determined.84 
In a similar fashion, the addition of the [Ga]DOTA entity to the N-terminus of 
peptide sequences is expected to produce similar fragmentation profile: an isotopic 
signature that will enable differentiation of b fragments, facilitating sequence 
determination. It is expected that MALDI tandem mass spectrometry is a reliable method 
for the deconvolution of such peptide sequences. 
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In addition to the difficulties in fully predicting the fragmentation of a peptide, the 
amino acids present, the three-dimensional conformation of peptides, and the presence of 
a chelator and metal complex will also interfere with the mass spectrometry data 
obtained. It can affect proton movement within the peptide, and possibly direct to a few 
favourable fragmentation pathways. As such, the peculiarities of the addition of DOTA 
and gallium to peptide fragmentation should be addressed in order to establish MALDI 
tandem mass spectrometry as the method of choice for sequence deconvolution of 
gallium-containing peptide libraries. 
 
2.2 Results and Discussion 
This chapter will outline the analysis of the fragmentation pattern of a test peptide 
containing the [Ga]DOTA motif at the N-terminus. The synthesis of a [Ga]DOTA-
octapeptide will first be discussed, followed by the analysis of MALDI TOF/TOF tandem 
mass spectrometry data with remarks being made on how to overcome possible 
limitations and adapt this methodology to be used in the sequence deconvolution of 
[Ga]DOTA-containing libraries. 
 
2.2.1 Synthesis of [Ga]DOTA Peptides 
The first step for the synthesis of a [Ga]DOTA-containing OBOC peptide library 
is to analyze the method of choice for sequence deconvolution. There are no reports on 
the typical fragmentation of gallium-containing peptides using MALDI tandem mass 
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spectrometry, and as such, in order to establish this method for this particular study, 
peptides containing a [Ga]DOTA complex were synthesized on Rink Amide resin using 
standard Fmoc peptide synthesis protocols. Since non-radioactive gallium labeling and 
further analysis of the peptides was performed off resin, an acid-labile resin is chosen as 
the solid support for this synthesis. 
The sequences of the three peptides synthesized were based on a sequence that 
has previously been reported to show good fragmentation patterns when utilizing MALDI 
TOF/TOF mass spectrometry (QATDKFTF-NH2).88 Compound 2.1 became the standard 
peptide sequence for such testing in our lab. The first peptide synthesized, compound 2.2 
contains the [Ga]DOTA complex on the N-terminus of the peptide sequence, in order to 
understand the effects of the presence of gallium and the bifunctional chelator to the 
fragmentation of a peptide, as a preliminary analysis. After this first analysis, two other 
peptides were synthesized, with small changes to the peptide sequence in order to 
accommodate the [Ga]DOTA complex and also avoid issues with cyclization that might 
be present when adding such a chelator and having an amino acid with a free amine on its 
side chain. Compound 2.3 contains the complex in the fourth amino acid of its sequence, 
while 2.4 contains it in the C-terminus of the peptide, on a lysine side chain (Scheme 
2.2). 
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Scheme 2.2 Synthesis of [Ga]DOTA peptides. Sequences on 2.3 and 2.4 are 
variations from 2.1. In 2.2, the chelator (DOTA) is added after a last Fmoc deprotection 
in a standard solid phase peptide synthesis procedure. In 2.3 and 2.4, the chelator is added 
before the peptide sequence is completed, after selective Mtt deprotection using 1.8% 
TFA in DCM. 
 
 
The major goal when changing the position of the [Ga]DOTA complex was to 
study the possibility of designing a library where the position of the chelator with the 
metal could also be randomized, like the position of regular amino acids. 
For 2.2, the Fmoc group on the N-terminus of the peptide was removed using 
standard conditions. The bifunctional chelator (DOTA) is then coupled to the N-terminus 
utilizing standard amino acid coupling using HCTU and DIPEA in DMF. For compounds 
2.3 and 2.4, the use of a orthogonal group is necessary in order to selectively deprotect 
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the side chain of a lysine, where the chelator will be coupled, leaving the Fmoc group on 
the terminal amine of the lysine. In order for this to happen, instead of using regular 
Fmoc-Lys(Boc)-OH, for these two peptides, Fmoc-Lys(Mtt)-OH was used. When 
synthesizing compound 2.3, after the coupling of lysine, the Fmoc group is kept and the 
4-methyltrityl (Mtt) group from the side chain of lysine is removed selectively using a 
solution of 1.8% TFA in dichloromethane (DCM), 9 times for 3 minutes until the solution 
colour comes from yellow to clear.  The same approach is used on 2.4, where lysine is the 
first amino acid to be added. The chelator is then coupled using the same reagents as for 
2.2. After the coupling of the chelator, the addition of the remaining amino acids is 
carried on using standard procedures. 
 For simplicity the gallium coordination of these compounds is conducted off 
resin after purification. To remove the peptides from resin and also have side chain 
groups deprotected, a solution of 95% TFA : 2.5% H2O :  2.5% TIS, known as Reagent 
K, is added to the resin for a period of three hours. This results in a solution containing a 
peptide with a C-terminal amide. These compounds were purified by HPLC (high-
performance liquid chromatography) and their identity confirmed by mass spectrometry. 
Gallium coordination is performed using gallium chloride (GaCl3) in an acetate buffer 
solution (NaOAc/Hac, pH 4), since under basic conditions, gallium will form insoluble 
gallate ions [Ga(OH)4-].89 The procedure for non-radioactive gallium coordination is well 
known and straightforward, where the coordinated compound can be easily separated 
from the non-labeled. The processes of resin removal and side chain deprotection as well 
as the non-radioactive gallium labeling for all three peptides are shown in Scheme 2.3. 
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Scheme 2.3 Side chain deprotection, removal from resin and gallium coordination 
for 2.2, 2.3 and 2.4. 
 
2.2.2 MALDI Tandem Mass Spectrometry 
As previously mentioned, MALDI tandem mass spectrometry use on [Ga]DOTA 
peptides has never been reported, leading to the necessity to perform initial studies on 
purified peptides in order to investigate the viability of this method as well as observe 
how the addition of this metal-chelator complex will affect the fragmentation profile for 
peptides.  
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The peptides were dissolved in water and mixed with an equal volume of a 
solution of trans-α-cyano-4-hydroxycinnamic acid (CHCA), which is one of the most 
commonly used matrices for short peptides on MALDI tandem mass spectrometry. The 
resulting solution was spotted on a MALDI target plate and the contents allowed to 
slowly evaporate. The matrix then absorbs light from a laser, which results in ablation 
and the transfer of a proton to the peptide, leading to detection.  Results obtained show 
the expected mass for all peptides and a very characteristic gallium 69/71 isotopic 
signature (Figure 2.4). The masses of the peptides are then selected for further 
fragmentation. 
 
Figure 2.4 MALDI tandem mass spectrometry for compound 2.5 showing the 
desired mass of the product. The zoomed frame shows the typical gallium isotopic 
signature, where the 69 isotope is relatively more abundant (60%) than the 71 isotope 
(40%). 
 
All compounds showed strong signals from MALDI tandem mass spectrometry, 
and when peaks are selected for further fragmentation, these gallium-containing peptides 
give a well-defined, clear fragmentation pattern that can be used to obtain the amino acid 
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sequences, where b series fragments are more abundant. However, compound 2.5 shows 
a higher number of distinguishable fragments (Figure 2.5). It is possible to identify clear 
fragments for the b series and y series on 2.5, while for 2.6 and 2.7, fragmentation does 
not provide well-defined peaks for b and y series. 
 
Table 2.1 Fragment assignment from b and y series for compound 2.5. [M+H]+ m/z 
= 1408.5475 (gallium-69 peak). 
 
Series Label Fragment 
Peak 
(m/z) 
Difference 
between 
Amino  
Acid 
        peaks Assignment 
  b0 [Ga]DOTA -------- --------  --------  
  b1 [Ga]DOTA-Q 581.17 --------   Glutamine 
  b2 [Ga]DOTA-QA 652.21  71.04  Alanine 
  b3 [Ga]DOTA-QAT 753.25 101.04   Threonine 
b  b4 [Ga]DOTA-QATD 868.27  115.02  Aspartic Acid 
series  b5 [Ga]DOTA-QATDK 996.34  128.07  Lysine 
  b6 [Ga]DOTA-QATDKF 1143.39  147.05  Phenylalanine 
  b7 [Ga]DOTA-QATDKFT 1244.45  101.06  Threonine 
  b8 [Ga]DOTA-QATDKFTF 1391.50 147.05   Phenylalanine 
            
  y1  --------   --------   --------   -------- 
  y2  --------  --------  --------   -------- 
y  y3  FTF 413.12   --------     --------   
 series y4  KFTF  541.33 128.21   Lysine 
  y5  DKFTF  --------  --------    -------- 
  y6  TDKFTF  757.40  --------  Threonine  
  y7  ATDKFTF  828.44  71.00  Alanine 
  y8  [Ga]DOTA-QATDKFTF  --------  --------  Glutamine  
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Figure 2.5 MALDI tandem mass spectrum for compound 2.5. The b series 
fragments can be easily identified. 
 
For 2.6 and 2.7, there is a prevalence of gallium-containing ions, meaning not all 
y and b fragments are easily identified (Figures 2.6 and 2.7). For 2.6, it is only possible 
to identify b fragments for higher masses, where the isotopic signature can be visualized, 
making it a challenge to predict the first few amino acids of the peptide sequence. For 
2.7, it is even harder to assign the correct peaks and only y1 and y7 can be easily 
visualized. Even though these particular sequences can be determined, the absence of 
peaks and difficulties in assigning the correct corresponding mass for a single peak can 
add an extra challenge when attempting to determine peptide sequences containing the 
[Ga]DOTA complex in randomized positions. 
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Table 2.2 Fragment assignment from b and y series for compound 2.6.  [M+H]+ m/z 
= 1351.5503 (gallium-69 peak). 
 
Series Label Fragment Peak  
Difference 
between Amino Acid 
   
(m/z) peaks Assignment 
 
b1 H-A --------  --------  --------  
 
b2 H-AA --------  --------  --------  
 
b3 H-AAT --------  --------  --------  
b  b4 H-AATD --------  --------          -------- 
series b5 H-AATDK([Ga]DOTA) 939.2092 --------  --------  
 
b6 H-AATDK([Ga]DOTA)F 1086.2496 147.0404 Phenylalanine 
 
b7 H-AATDK([Ga]DOTA)FT 1187.2853 101.0357 Threonine 
 
b8 H-AATDK([Ga]DOTA)FTF 1334.2766 146.9913 Phenylalanine 
            
  y1  F --------     --------    --------  
  y2  TF    --------   --------    --------  
y  y3  FTF --------    --------    --------   
series  y4 K([Ga]DOTA)FTF  995.2423* --------   --------  
  y5  DK([Ga]DOTA)FTF 1108.2667  115.0244  Aspartic Acid  
  y6  TDK([Ga]DOTA)FTF 1209.2937  101.027  Threonine  
  y7  ATDK([Ga]DOTA)FTF --------  --------  --------  
  y8  AATDK([Ga]DOTA)FTF --------  --------  --------  
  * Corresponds to the gallium-71 peak. 
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Figure 2.6 MALDI tandem mass spectrum for compound 2.6. The b ions can be 
easily identified when containing the [Ga]DOTA complex, however, lower mass 
fragments are not easily identified. 
 
For a matter of comparison, a fourth peptide was synthesized, containing a 
[Ga]DOTA motif on the N-terminus, but substituting the glutamine residue by an alanine 
(2.8) (Figure 2.8). By performing such change, it is possible to establish a closer 
comparison between products 2.6, 2.7 and 2.8 on their fragmentation profiles. The 
fragmentation profile of 2.9 is shown on Figure 2.9. 
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Figure 2.7 MALDI tandem mass spectrum for compound 2.7. The b ions cannot be 
easily identified. Ions containing the [Ga]DOTA motif can be better identified; however, 
it is challenging to assign fragments for this sequence. 
 
 
 
 
 
 
Figure 2.8 Structure of compounds 2.8 and 2.9, which are a variations of 
compound 2.2 and 2.5, and shows a structure that is similar to 2.6, being the position of 
the [Ga]DOTA surrogate the only major difference. 
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Figure 2.9 MALDI tandem mass spectrum for compound 2.9. The b series 
fragments can be easily identified. 
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Table 2.3 Fragment assignment from b and y series for compound 2.9. [M+H]+ m/z 
= 1351.1435 
 
Series Label Fragment 
Peak 
(m/z) 
Difference 
between 
Amino  
Acid 
        peaks Assignment 
  b0 [Ga]DOTA -------- --------  --------  
  b1 [Ga]DOTA-A 524.01 --------   Alanine 
  b2 [Ga]DOTA-AA 595.03  71.04  Alanine 
  b3 [Ga]DOTA-AAT 696.05 101.04   Threonine 
b  b4 [Ga]DOTA-AATD 813.04  115.02  Aspartic Acid 
series  b5 [Ga]DOTA-AATDK 939.13  128.07  Lysine 
  b6 [Ga]DOTA-AATDKF 1086.16  147.05  Phenylalanine 
  b7 [Ga]DOTA-AATDKFT 1187.16  101.06  Threonine 
  b8 [Ga]DOTA-AATDKFTF 1334.14 147.05   Phenylalanine 
            
  y1  --------   --------   --------   -------- 
  y2  --------  --------  --------   -------- 
y  y3  FTF 413.12   --------     --------   
 series y4  KFTF   --------  --------   -------- 
  y5  DKFTF  --------  --------    -------- 
  y6  TDKFTF   --------  --------   --------  
  y7  ATDKFTF  828.23   --------   -------- 
  y8  [Ga]DOTA-QATDKFTF  --------  --------   -------- 
 
 
2.3 Conclusions 
The results obtained during the investigation of the fragmentation patterns of 
gallium-containing peptides gives useful information regarding the effects of the addition 
of a chelator and a metal to different positions on a peptide chain. These results have 
shown the first sequencing of [Ga]DOTA-containing peptides, showing the gallium 
isotope signature, which assists with the determination of b versus y ions, it also provides 
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starting point for further research on the identification of peptide sequences obtained 
from a [Ga]DOTA-containing OBOC peptide library for the development of imaging 
agents. 
Similar peptide sequences were used for this experiment, with the only change 
being in the position of the [Ga]DOTA motif. Compounds containing the complex in the 
N-terminus were successfully sequenced, while the sequencing of peptides containing the 
complex in different positions within the peptide chain was challenging due to the 
absence of a few fragment peaks. This would raise a concern in the synthesis of a library 
containing the [Ga]DOTA complex in a random position within the peptide sequence. 
The results shown proved that MALDI TOF/TOF is a reliable method for the 
sequence determination of gallium-containing OBOC peptide libraries. 
 
2.4 Experimental Methods 
2.4.1 General Materials and Procedures 
All chemicals and solvents were purchased from commercially available sources 
and used without further purification.  Fmoc amino acids, coupling reagents and Rink 
Amide MHBA (4-(2’,4’-dimethoxyphenyl-(9-fluorenylmethoxycarbonyl)-aminomethyl)-
phenoxy-acetamidonorleucyl-4-methyl benzhydrylamine resin resin were purchased from 
Peptides International (Louisville, KY) or Aapptec (Louisville, KY).   
Solvents were purchased from Fisher Scientific and Sigma-Aldrich. Analytical 
HPLC was performed using a Waters Sunfire C18 column 4.6 x 150 mm, 5 µm, while 
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semi-preparative HPLC was performed utilizing a Waters Sunfire Prep C18 OBD column 
19 x 150 mm, 5 µm. The gradient system consists of acetonitrile + 0.1% TFA (Solvent A) 
and water + 0.1% TFA (Solvent B).  Ultraviolet absorbance measurements were obtained 
utilizing a Waters 2998 Photodiode Array Detector and Mass spectra were obtained via 
electrospray ionization utilizing a Micromass Quatro Micro LCT mass spectrometer.   
MALDI mass spectrometry experiments were done utilizing an Applied 
Biosystems 4700 PDS, equipped with a Nd: YAG laser tuned to a wavelength of 355 nm, 
with a 200 Hz laser rate operating in reflectron mode and tandem time-of-flight ion 
detectors in series.  The instrument was calibrated with a mixture of angiotensin I (m/z 
1296.685), Glu-1-Fibrino-peptide B (m/z 1570.677) to a mass accuracy of ± 0.5 Da. 
 
2.4.2 General Peptide Synthesis 
Standard Fmoc solid phase peptide synthesis (SPPS) procedures were utilized to 
obtain the desired peptides containing all side chain protecting groups. Rink amide 
MHBA NH2 resin (0.1 mmol, 0.52meq/g) containing a Fmoc protecting group was used. 
The resin was swelled using DCM washes, and the Fmoc group was removed using a 
20% piperidine in DMF solution (2x, 5 min and 20 min, respectively). 
The deprotection solution was removed from resin using a series of DMF and 
DCM washes. Fmoc protected amino acids (0.3 mmol, 3 eq) were dissolved in 
approximately 0.5 mL DMF, along with HCTU (0.3 mmol, 3 eq) and DIPEA (0.6 mmol, 
6 eq). For the peptides described above, the amino acids used were: Fmoc-Phe-OH, 
Fmoc-Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ala-OH and 
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Fmoc-Gln(Trt)-OH.  The solution of coupling reagents plus activated amino acid was 
then combined with the resin and agitated for one hour. The resin was then washed with 
DMF and DCM multiple times. This process of coupling and deprotection was then 
repeated until the desired sequence of the peptides was obtained. Kaiser test90 was 
performed to confirm the presence of free primary amino groups after deprotection and 
the absence after coupling of amino acids. For each peptide sequence, the deprotection 
step preceding the addition of the chelator DOTA was performed in different steps of the 
synthesis, using different reagents, which will be specified below. 
(DOTA)QATDKFTF-NH2 (2.2) 
 After a last Fmoc deprotection, the chelator DOTA, in its tBu-protected form 
(tris-tBu-DOTA) was added manually by the use of solid phase peptide synthesis 
techniques (4 eq, 0.4 mmol), using HCTU (4 eq, 0.4 mmol) and DIPEA (8 eq, 0.8 mmol) 
as coupling reagents. 
H-AATDK(DOTA)FTF-NH2 (2.3)  
Peptide synthesis is performed as described on 2.4.2 until the coupling of the 
second phenylalanine. For the next coupling Fmoc-Lys(Mtt)-OH is used instead of Fmoc-
Lys(Boc)-OH. Before removing the Fmoc group from the lysine, a Mtt deprotection is 
performed using a 1.8% TFA solution in DCM (9x, 3 minutes). The chelator DOTA, in 
its tBu-protected form (tris-tBu-DOTA) was added manually using standard solid phase 
peptide synthesis techniques (4 eq, 0.4 mmol), using HCTU (4 eq, 0.4 mmol) and DIPEA 
(8 eq, 0.8 mmol) as coupling reagents. After coupling the chelator, the Fmoc group from 
lysine was removed, and the remaining of the peptide was built up to completion. 
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H-AATDFTFK(DOTA) (2.4) 
 Following a very similar procedure to compound 2.3, here, Fmoc-
Lys(Mtt)-OH is used. After the first coupling step, before removing the Fmoc group from 
the lysine, a Mtt deprotection is performed using a 1.8% TFA solution in DCM (9x, 3 
minutes), until change of colour from clear to yellow was no longer observed. The 
chelator DOTA, in its tBu-protected form (tris-tBu-DOTA) was added manually using 
standard solid phase peptide synthesis techniques (4 eq, 0.4 mmol), using HCTU (4 eq, 
0.4 mmol) and DIPEA (8 eq, 0.8 mmol) as coupling reagents. After coupling the chelator, 
the Fmoc group from lysine was removed, and the remaining of the peptide was built up 
to completion. 
(DOTA)AATDKFTF-NH2 (2.8) 
After a last Fmoc deprotection, the chelator DOTA, in its tBu-protected form 
(tris-tBu-DOTA) was added manually by the use of solid phase peptide synthesis 
techniques (4 eq, 0.4 mmol), using HCTU (4 eq, 0.4 mmol) and DIPEA (8 eq, 0.8 mmol) 
as coupling reagents. 
 
2.4.3 Peptide Deprotection, Cleavage and Purification 
After the chelator coupling, the peptide was mixed with 5 ml of a solution of 95% 
TFA, 2.5% H2O and 2.5% TIS for six hours to remove the peptide from resin, as well as 
remove side-chain protecting groups.  The resulting solution was cooled on ice and cold 
tert-butyl methyl ether (TBME) (20 mL) was added to the solution until a white 
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precipitate formed.  The solution was then centrifuged at 0oC at 3000 rpm for 10 minutes.  
The liquid was decanted and the resulting pellet was mixed with another 20 mL of cold 
TBME and subsequently centrifuged again under identical conditions to obtain the crude 
peptide. Following the removal of the supernatant, the peptide pellets were dissolved in 
water, frozen at -78°C and lyophilized. Small samples of the resin were cleaved using the 
full deprotection procedure in order to monitor reaction completion. 
The crude peptides were dissolved in water, purified by HPLC (15 min linear 
gradient 15% solvent A in solvent B to 70%) and identified by mass spectrometry, giving 
white powders after lyophilization. 
(DOTA)QATDKFTF-NH2 (2.2) 
Purity: >95% [M+H]+ m/z calc: 1342.66   obs: 1342.94.  
H-AATDK(DOTA)FTF-NH2 (2.3)  
Purity: >99% [M+H]+ m/z calc: 1285.42   obs: 1285.93 
H-AATDFTFK(DOTA) (2.4) 
Purity: >99% [M+H]+ m/z calc: 1285.42  obs: 1285.99 
(DOTA)AATDKFTF-NH2 (2.8) 
Purity: >99% [M+H]+ m/z calc: 1286.42   obs: 1286.01 
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2.4.4 Cold Ga Coordination Procedures 
The procedures here stated correspond to compounds 2.5, 2.6, 2.7 and 2.9. 
10 mg of each DOTA-peptide, dissolved in 0.1 M pH 4 NaOAc/HOAc buffer 
were added to a round bottom flask containing 5 mg of GaCl3. The mixture was stirred at 
room temperature for 30 minutes, then heated to 70o C and stirred for another 30 minutes. 
The resulting mixture was cooled prior to purification using a light C18 RP Sep-Pak© 
cartridge. The reaction mixture was passed through the Sep-Pak©, and the cartridge was 
washed with 10 mL of water in order to remove unreacted GaCl3. Ethanol is then used to 
wash out the labeled product. The EtOH was then removed in vacuo.  
 [Ga]DOTA-QATDKFTF-NH2 (2.5) 
Purity: >98% MS (MALDI) [M+H]+ m/z calc: 1408.56 obs: 1408.63 (Gallium-71) 
H-AATDK([Ga]DOTA)FTF-NH2 (2.6)  
Purity: 90% MS (MALDI) [M+H]+ m/z calc: 1353.13 obs: 1353.55 (Gallium-71) 
H-AATDFTFK([Ga]DOTA)-NH2 (2.7) 
Purity: >90% MS (MALDI) [M+H]+ m/z calc: 1353.54 obs: 1353.89 (Gallium-71) 
[Ga]DOTA-AATDKFTF-NH2 (2.9) 
Purity: >90% MS (MALDI) [M+H]+ m/z calc: 1353.13 obs: 1353.52 (Gallium-71) 
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2.4.5 MALDI Tandem Mass Spectrometry  
Purified peptides were dissolved in water to a final concentration of 
approximately 0.1 mg/mL. A portion of the peptide solutions (3 µL) and a equal portion 
of CHCA (matrix) solution (3 µL) were mixed for a few minutes before spotting. CHCA 
is a mixture of 50:50 acetonitrile/water with 0.1% TFA (v/v) at a concentration of 5 
mg/mL. A portion of the peptide/matrix mixture (70 µL) was spotted onto a MALDI 
target plate in duplicate for further analysis. The spotted mixture is allowed to evaporate, 
resulting in the co-crystallization of the matrix with the peptide. Samples were then 
analysed using MALDI tandem mass spectrometry. The spectra obtained show gallium-
69/71 typical isotopic distributions, being the 69 isotope 60% abundant in nature, while 
the 71 isotope corresponds to 40%. The gallium-69 peak was chosen for fragmentation 
via CID with argon gas. Tandem mass spectra were obtained and peaks assigned by 
manual peptide analysis. 
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3 Chapter 3: Synthesis, Coordination and Sequence 
Deconvolution of a [Ga]DOTA-Octapeptide on TentaGel Resin 
 
3.1 Introduction 
Since the advent of OBOC, TentaGel resin is the solid support of choice, as it is 
stable under acidic and basic conditions required for the removal of protecting groups of 
peptides. In TentaGel resin, polyethylene glycol (PEG) units of approximately 3 kDa are 
cografted onto a low-cross-linked-polystyrene.91 This structure gives TentaGel the ability 
of swelling in both organic solvents and water, which makes it suitable for cell studies, 
where the peptide sequences to be tested should be on resin to allow for screening and 
better visualization. Furthermore, it also allows for the projection of attached groups into 
solution rather than anchored closer to the polymer backbone. 91 
Libraries are synthesized using a split-mix procedure, which will lead to different 
peptide sequences with the same length, where one individual 90 µm bead contains 
approximately 1013 copies of only one peptide sequence.49,50 Here, a single bead should 
be able to provide strong enough signal for MALDI tandem mass spectrometry, meaning 
that a single bead should have enough material to be detected by the mass spectrometer 
and for further fragmentation. Considering that the sensitivity of the MALDI time-of-
flight (TOF) instrument is in the order of pmol, and the amount of material available from 
a single TentaGel bead (0.29 meq) is in the range of 10-10 mol, one bead provides enough 
peptide material for fragmentation.92 However, since most cleavage protocols are not able 
to totally remove a peptide off resin, and the presence of bulk from the chelator and 
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gallium complex may interfere with the number of sites available to a reacting molecule, 
test sequences were built on TentaGel using a cleavable linker in order to simulate the 
sequence deconvolution from a single bead. 
 
3.2 Results and Discussion 
3.2.1 Choice of a Suitable Linker 
In order to obtain the sequences of positive peptides from an OBOC library using 
MALDI tandem mass spectrometry, the peptide has to be successfully cleaved off resin 
after screening without damaging its structure or producing significant byproducts that 
might interfere with its fragmentation and sequence deconvolution. For this to happen, a 
stable linker is coupled to the resin before the peptide sequence is built. 
When choosing a suitable linker, some important characteristics should be 
considered, such as the stability of the linker on resin under synthesis and screening 
conditions, how efficient is the process of peptide removal from resin, and the presence 
of other cleavage byproducts that can interfere with fragmentation and consequent 
sequence deconvolution. Two linkers often used in solid phase peptide synthesis (SPPS) 
were evaluated. Both linkers were added to TentaGel resin, and a peptide sequence was 
built thereafter (QATDKFTF). The two linkers used were 2-amino-3-(2-
nitrophenyl)propanoic acid (ANP), linker, which was previously used in our lab63, and a 
methionine linker, that is commonly used when light sensitivity becomes an issue.93 
The two peptides were cleaved off-resin and analyzed by MALDI tandem mass 
spectrometry for sequence determination, which showed good fragmentation results with 
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both linkers (Figure 3.1). However, when using the methionine linker, a large number of 
impurities or byproducts are present, due to its chemical cleavage mechanism, leading to 
the presence of unwanted fragments that can interfere with the sequence analysis. In 
addition to that, during the chemical reaction that removes the bead from resin, there is 
the formation of a homoserine lactone on the C-terminus of the peptide, which might 
change the peptide fragmentation profile, and make the sequencing process more 
challenging. 
The ANP linker, on the other hand, leaves an amide on the C-terminus of the 
peptide, which removes the extra challenge of accounting for an extra mass on some 
fragments. Furthermore, it provides clean spectra, as its light-dependent cleavage 
mechanism does not produce any significant byproduct.  
Due to its easy manipulation, simple cleavage protocol and the fact that it 
provided clearer results when compared to the methionine linker, the ANP linker became 
the linker of choice for the design of the [Ga]DOTA OBOC  peptide library. The 
coupling step to add the ANP linker to resin is shown on Scheme 3.1. Although the 
mechanism for ANP off-resin cleavage is not completely understood, it has been 
proposed to relate to the electronic excitation of 2-nitrobenzyl compounds, via a 1-5 
proton shift, which quickly generates their aci-nitro tautomers (Figure 3.2).94,95  
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Figure 3.1 a) MS/MS spectrum for QATDKFTF-NH2 obtained from a chemical 
cleavage using the methionine linker. After cleavage, there is the formation of a 
homoserine lactone in the C-terminus of the peptide. b) MS/MS spectrum for 
QATDKFTF-NH2 obtained used the photocleavable linker ANP. This linker gives a clear 
spectrum as it does not contain traces of chemicals. 
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Scheme 3.1 Coupling of ANP linker to TentaGel resin prior to the addition of 
Fmoc protected amino acids. 
 
 
 
Figure 3.2 a) Structure of ANP linker b) formation of aci-nitro tautomers for 2-
nitrobenzyl compounds, suggested to be the first step on the cleavage mechanism of ANP 
linker. 
 
3.2.2 Peptide Synthesis and Gallium Labeling on Resin 
The peptide synthesis on TentaGel is performed in a similar fashion to the 
synthesis on Rink Amide resin, with the only difference being the addition of the ANP 
linker prior to building up the peptide sequence. Reagent K is used to remove the amino 
acids side chains, but in the case of TentaGel, it does not remove the peptide off-resin. 
TentaGel contains a free amine, which forms an amide bond once amino acids are 
attached. Therefore, the regular acidic cleavage conditions used to remove side-chain 
protecting groups are not able to remove the peptide from resin. 
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For this experiment, the gallium labeling procedure was performed on resin, in an 
attempt to simulate the library synthesis. As the peptide synthesis is conducted in organic 
solvents, the TentaGel beads do not mix appropriately with the aqueous buffer solution 
containing gallium chloride, which might cause incomplete on-resin coordination. 
Therefore, an elaborate washing procedure that will eliminate as much traces of organic 
solvent as possible is a fundamental step before gallium coordination on resin.  
The initial attempts for coordinating gallium to DOTA on TentaGel resin were not 
successful. With the addition of a greater excess of GaCl3, an optimized series of organic 
solvent and water washes and a longer time for the reaction, complete coupling was 
achieved and confirmed using MALDI tandem mass spectrometry (Figure 3.3).  
 
Figure 3.3 a) MS spectrum for [Ga]DOTA-QATDKFTF-NH2 showing incomplete 
gallium coordination on resin, as it shows two major peaks corresponding to the DOTA-
peptide with and without gallium. b) MS spectrum for [Ga]DOTA-AATDKFTF-NH2 
showing complete gallium coordination on resin after increasing reaction time and the 
concentration of GaCl3 (from 5 to 10 equivalents). 
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3.2.3 Sequence Deconvolution 
For sequence deconvolution, the positive beads are placed in wells on a 96-well 
plate with 40 µL of water. Peptide beads were then exposed to a 365 nm light source for a 
period of 4 hours to cleave peptides from resin. 
MALDI tandem mass spectrometry results showed not only that it is possible to 
obtain enough material to be detected by the mass spectrometer and also to produce 
visible fragments, but that is also possible to perform cold gallium labeling on TentaGel 
resin, by using an excess of gallium chloride in NaOAc/AcOH buffer (pH =5), in a 
procedure similar to the regular peptide cold gallium coordination described in the 
previous chapter, as already shown on Figure 3.3.  Proof that a single bead provides 
enough material for sequence determination is given on Figure 3.4, where the fragment 
assignments for the test peptide can be observed, predominantly b ions. 
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Figure 3.4 MS/MS spectrum for peptide [Ga]DOTA-AATDKFTF-NH2 obtained 
from a single bead. Here, b ions can be easily identified and the peptide sequence can be 
readily obtained. 
 
3.3 Conclusions 
The screening of OBOC libraries is performed on resin, while for the 
deconvolution of positive sequences using MALDI tandem mass spectrometry, the 
peptide must be off resin. For this to happen, it is necessary to place a stable linker on 
resin prior to building the peptide sequence. Of the two linkers tested, the ANP linker 
showed better results, as it provides a cleaner spectra when compared to the methionine 
linker. The reason for this difference may be due to the presence of chemical reagents in 
the methionine linker samples that are analyzed by MALDI tandem mass spectrometry, 
due to its cleavage protocol. 
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Using ANP as a linker, 69/71Ga was successfully coordinated on resin after 
optimization of the amount of reagent used and the reaction time. Furthermore, peptide 
sequences can be determined for this gallium-peptide using only a single bead for 
analysis. The signal obtained is strong enough to easily identify correspondent peaks 
leading to amino acid assignments, with b ions more common than y ions for the 
sequence used. 
Considering the combination of positive results acquired for the gallium-
containing model peptide, we were confident to proceed to the synthesis, screening and 
sequence deconvolution of a gallium-containing peptide library. 
 
3.4 Experimental Methods 
Chemicals and solvents were purchased and used without further purification. 
Resin, Fmoc amino acids and coupling agents were purchased from Peptides 
International (Louisville, KY) or Aapptec (Louisville, KY), unless stated otherwise. 
Solvents were purchased from Fisher Scientific and Sigma Aldrich. 
The automated peptide synthesis was performed using a Biotage® Syro WaveTM 
Peptide Synthesizer. MALDI tandem mass spectrometry experiments were performed 
using an Applied Biosystems 4700 PDS, equipped with an Nd: YAG laser tuned to a 
wavelength of 355 nm. The instrument was calibrated using a mixture of angiotensin I 
(m/z 1296.685), Glu-1-Fibrino-peptide B (m/z 1570.677) to a mass accuracy of ± 0.5 Da. 
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3.4.1 Peptide Synthesis using different linkers 
Standard Fmoc solid phase peptide synthesis was performed to obtain the 
peptides. Tentagel S NH2 resin (0.1mmol, 0.29 mmol/g) containing a Fmoc protecting 
group was utilized. The resin was swelled with DCM washes. A solution of 20% 
piperidine was used to remove the Fmoc group (1x 5min, and 1x 15 minutes, 
respectively) followed by DMF and DCM washes. Either Fmoc-ANP linker or Fmoc-
methionine (0.3 mmol, 3 eq) were dissolved in approximately 5 mL DMF along with 
HCTU (0.3 mmol, 3 eq) and DIPEA (0.6 mmol. 6 eq). The aminoacids coupled after the 
linker were: Fmoc-Phe-OH, Fmoc-Thr (tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-
Asp(OtBu)-OH, Fmoc-Ala-OH and Fmoc-Gln(Trt)-OH. A final Fmoc deprotection and 
side chain deprotection were performed before following the cleavage protocols. The 
cleavage cocktail used for side chain deprotection consisted of 95% trifluoroacetic acid 
(TFA), 2.5% triisopropylsilane (TIS) and 2.5% H2O. 
 
3.4.2 Chemical Cleavage Protocol 
Peptide beads were isolated using a microscope and placed in a 96-well plate with 
conical bottom with 40-50 µL of water. The liquid was allowed to evaporate overnight 
before 20-30 µL of a 0.25 M CNBr in 70% aqueous formic acid solution was added to 
each well and left for 12 hours at room temperature. The wells were then washed 3 times 
with 30 µL of water. The contents of the wells were allowed to evaporate in between 
washes. The final product was kept in 40-50 µL of water prior to MALDI analysis. 
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3.4.3 Photocleavage Protocol 
Peptide beads were isolated using a fluorescent microscope and placed 
individually on wells on a 96-well plate with approximately 40-50 µL of water. The 
peptide beads were then exposed to a 365 nm light source for a period of 4 hours, 
replenishing the volume of water to 40-50 µL frequently, in order to prevent the wells 
containing the beads from drying, which could lead to peptide degradation.  
 
3.4.4 MALDI Tandem Mass Spectrometry Analysis 
After following the different cleavage protocols, 2 µL of each peptide solution 
obtained was mixed with 2 µL of α-Cyano-4-hydroxycinnamic acid (CHCA) matrix for 5 
minutes.  An aliquot of 0.75 µL of this mixture was spotted onto a MALDI target plate in 
duplicate for analysis. The solvent was allowed to evaporate, leading to a co-
crystallization of the matrix and peptide. The samples were then analyzed utilizing 
MALDI tandem mass spectrometry. 
 
3.4.5  Peptide Synthesis on TentaGel 
Peptide synthesis was performed using the automated peptide synthesizer, on 
TentaGel S NH2 resin. The sequences built were the same described on section 2.4.2. 
The first step, coupling the Fmoc-ANP linker was performed manually. The resin 
was swelled in DCM, Fmoc deprotection was performed and the linker was dissolved in 
DMF and added to the resin along with HCTU (4 eq, 0.4 mmol) and DIPEA, (8 eq, 0.8 
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mmol). The mixture was then stirred for one hour, and the solution was removed from the 
vessels by DMF and DCM washes. The resin containing the ANP linker was then 
transferred to an automated peptide synthesizer vessel and the peptide synthesis was 
carried on, following the same procedures stated on 2.4.2. 
After proceeding with automated synthesis, the chelator coupling was also 
performed manually, after a final Fmoc deprotection. 
Samples were analyzed by MALDI tandem mass spectrometry to check for the 
presence of the desired peptide (mass). 
 
3.4.6 Peptide Side Chain Deprotection 
Side chain deprotection was performed using a cocktail of 95% TFA, 2.5% water 
and 2.5% TIS, and the washing after 4 hours was performed as follow: 1) 3x DMF, 2) 2x 
MeOH, 3) 2x 5%DIPEA in DMF, 4) 3x DMF, 5) 3x MeOH, 6) 3x DCM, 7) 3x DMF, 8) 
3 x 50% DMF in water, 9) 5 x water. The peptides are then kept in water solution prior to 
gallium coordination and MALDI analysis. 
 
3.4.7 69/71Ga Coordination on TentaGel Resin 
TentaGel resin (10 mg) containing the peptide sequence of interest, was added to 
a small round bottom flask containing initially 5, and later on 10 mg of GaCl3 dissolved 
in 0.1 M pH 4 NaOAc/HOAc buffer. The mixture was stirred for 45 minutes at room 
temperature and another 45 minutes at 75o C. The resulting mixture was cooled to room 
temperature, added to a small peptide vessel, and washed with water multiple times. The 
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peptide beads were kept in water for further studies using MALDI tandem mass 
spectrometry. 
 
3.4.8 MALDI Analysis of a Peptide From a Single TentaGel Bead 
Beads were isolated using an Olympus IX70 inverted fluorescent microscope and 
placed individually on wells on a 96-well plate with around 50 µL of water and irradiated 
with UV light for a period of four hours. 
An aliquot of the peptide solution (2 to 4 µL) is mixed with an equal volume of 
CHCA matrix, and a portion (0.75 µL) was spotted onto a MALDI target in duplicate for 
mass spectrometry analysis. The solvent on the mixture is then allowed to evaporate. 
After that, samples were analyzed using MALDI tandem mass spectrometry, showing a 
typical gallium isotopic signature (69 and 71 isotopes). Tandem mass spectra were 
obtained and peaks assigned by manual de novo peptide analysis. 
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4 Chapter 4: Synthesis, Screening and Sequence Deconvolution 
of a Gallium-containing OBOC Peptide Library 
 
4.1 Introduction 
4.1.1 Breast Cancer 
Breast cancer is one of the most common cancers affecting Canadian women each 
year. In 2013, the Canadian Cancer Society estimated that 23,800 Canadian women will 
be diagnosed with breast cancer and approximately 5,000 would die from it.96 
The current standard diagnostic tools for tumour detection are mammography and 
ultrasound, which have been able to detect tumours at a relatively early stage.97 Over the 
years, the low sensitivity and specificity of these techniques have proven inefficient in 
patients with dense breast tissue, breast implants or postsurgical abnormalities98,99, and 
therefore, the need for the development of non-invasive diagnostic tools is of great 
interest. These tools will not only provide a better diagnosis for breast cancer but may 
also be able to provide information on the physiology of a tumour, disease progression 
and therapy response. 
Many efforts have been made to improve imaging detection in order to better 
discriminate between benign and malignant tumours, as well as to differentiate them 
based on their pathology.  One of the modalities recently studied for such matter is 
contrast enhanced magnetic resonance imaging (CE-MRI), which provides high 
sensitivity (over 90%), but still a low to moderate specificity for lesion characterization 
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(72%)100-102, which still makes it a challenge to differentiate between cancer and benign 
lesions, or aggressive versus non-aggressive tumours.103  
In PET imaging, 18F-FDG has been used to assess response to therapy or disease 
progression. Quantitative PET-CT is becoming a valuable tool for the assessment of 
individual response to therapy, as it accounts for changes in tumour size and metabolism. 
By calculating the changes in tumour standardized uptake values (SUVs), it is possible to 
evaluate a patient’s response to therapy and the disease progression. However, with the 
use of 18F-FDG and the available tools from PET-CT imaging, there is still significant 
interference from different error sources, compromising the ability to detect SUV 
changes, and even though it has become a useful tool for management of disease 
progression, especially regarding metastasis, it is still not reliable on the differentiation of 
some aggressive versus non-aggressive tumours, which is still a challenge when 
diagnosing breast cancer.104 
Although recent efforts were made in the field of non-invasive methods for breast 
cancer detection, mammography is still the more efficient test for the detection of breast 
tumours, even though it may still not discriminate tumours correctly.  
Relying on anatomic density and distortions, and byproducts of a cancer 
mammogram is far from ideal, leading to a need for more specific tests for the early 
efficient detection of aggressive breast tumours, which would not only increase the 
chances of survival, but also help improve therapy accordingly. The design of gallium-
containing peptide libraries aims to discover bioactive peptide sequences that can be 
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developed into PET imaging agents to be used as a non-invasive method for the early 
detection and determination of cancer aggressiveness of breast tumours. 
 
4.1.2 OBOC Library Screening 
One-bead one-compound combinatorial (OBOC) libraries have been successfully 
used to identify ligands for a large number of biological targets, using a variety of 
screening methods.50,61,105 In 1991, when the OBOC library concept was first reported, 
the library screening consisted in having acceptor molecules coupled to an alkaline 
phosphatase enzyme and added in soluble form to the peptide bead library. The positive 
beads were easily identified due to the intensive staining.49 
A method for the discovery of anti-cancer drugs was developed using beads 
containing 2 orthogonal linkers that release the bead-bound compound at different pH. 
Here, cells mixed with beads were plated in soft agarose containing cell culture medium. 
A portion of the peptide is released from the beads at neutral pH, and the cytotoxic effect 
is observed as a clear ring of tumour cell lysis. Positive beads are easily selected and the 
remaining of the compound is cleaved off resin for structural analysis.106 
Although very efficient, the use of enzyme-linked colorimetric assays have some 
limitations, especially regarding the presence of false positive interactions, usually 
corresponding to peptide beads binding to other screening agents such as secondary 
antibodies, streptavidin, and reporting enzymes. In order to overcome these limitations, a 
dual colour screening method was developed.107 This is a two-stage method that aims to 
rapidly identify compounds that bind only to a specific protein and monitor the intensity 
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of this interaction. The first stage consists in colorimetrically labeling nonspecific 
interactions with background proteins, and the second stage consists in colorimetrically 
labeling the beads with the target protein. For these two steps, beads are immobilized in 
agarose and scanned on flat-bed transparency scanner after the first and second stages. By 
using an image subtraction technique, the resulting image highlights beads that 
specifically bind the desired target protein.107,108 
With the advent of the automated bead sorter, the complex parametric analyzer 
and sorter (COPAS), which sorts positive beads based on size and fluorescence, studies 
where the target protein is conjugated to fluorescent dyes instead of enzymes were 
developed. These studies improved the efficiency of the screening of libraries by 
scanning an even larger number of compounds in a short period of time.81,109 
Although the described approaches are feasible for a variety of targets, during the 
purification and derivatization process prior to screening, these proteins can adopt an 
altered conformation that changes their function and interaction with bioactive peptides. 
In order to preserve the protein's conformation and enable proper display of biologically 
relevant epitopes110, the presence of the whole plasma membrane and binding partners 
are often used. Therefore, binding assays that utilize cells are still preferred as a primary 
method of library screening, and have been successfully utilized to discover ligands 
against a variety of human cancer cell lines such as breast cancer51 and Jurkat T-
leukemia.111 
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4.2 Results and Discussion 
4.2.1 OBOC Library Synthesis 
As previously described, it is possible to determine the sequence of a peptide from 
a single peptide bead when using the ANP linker. This allowed for the synthesis of a 
[Ga]DOTA-containing peptide library for screening against different cancer cell lines 
using standard solid phase peptide synthesis approaches. For the synthesis of this library, 
all natural amino acids were used, except cysteine and methionine. Cysteine has the 
ability to form disulfide bonds between peptide chains, thus adding some challenges 
during the sequencing process. On the other hand, methionine is known to be unstable to 
UV cleavage conditions and is also predisposed to oxidation.  
When constructing an eight amino acid library using eighteen natural amino acids, 
it would result in approximately 1010 possible sequences.  However, this would lead to 
the use of kilograms of resin, which becomes impractical. As a proof-of-concept, 1 g of 
resin beads were used in the design of this library, which allowed for the synthesis of 
approximately 1.5 million individual peptide sequences. 
The library synthesis followed a “split-mix” procedure. After manual Fmoc 
deprotection and coupling of Fmoc-ANP-OH to 1 g of resin, the resin was divided 
equally among 18 different wells on the peptide synthesizer, each corresponding to a 
different natural amino acid. Beads from each well were recombined after deprotection 
and coupling step, mixed thoroughly and divided again among the eighteen wells. This 
procedure was repeated until the desired length of the library was reached. This method 
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guaranteed that only one amino acid was coupled to each well in every step, allowed for 
sequence randomization and provided peptides of the same length. 
After eight coupling cycles, the resin was again recombined, and the coupling of 
DOTA, as well as gallium coordination, were performed manually. For DOTA, 4 
equivalents of the chelator on its tri-tBu protected form were added to the resin beads, 
together with 4 equivalents of HCTU and 8 equivalents of DIPEA.  
Side chain deprotection is achieved by using 8 mL of a TFA/H2O/TIPS mixture 
prior to gallium coordination, which is performed by using excess of GaCl3 in 
NaOAc/HOAc pH 4 buffer, in a procedure already described on chapter 3. The extra 
purification step, using a Sep Pak® cartridge was not necessary here, since the resin 
beads are retained in the peptide vessel when washing out unreacted gallium. 
The purity of the library is assessed through MALDI tandem mass spectrometry, 
prior to library screening. A total of 50 beads were selected from the library using a 
fluorescence microscope and were irradiated with UV light for four hours with 
approximately 40 µL of water.  The resultant mixtures were co-crystallized with CHCA 
and the MALDI tandem spectra were obtained and sequenced. Results showed the 
presence of only one peptide on each single bead, all containing eight amino acid 
sequences (Figure 4.1). 
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Figure 4.1 Samples from the [Ga]DOTA OBOC library showing the presence of 
only one peptide on a single bead. 
 
4.2.2 Library Screening 
For the screening of the designed library, we were looking to find peptides that 
would bind specifically to a more aggressive breast cancer cell line, MDA-MB-231, by 
screening the obtained library against those cells and later on performing a negative 
versus positive screening using MCF-7 cells, as both cells have a different receptor 
expression. MDA-MB- 231 cells expressing the tdTomato protein and MCF-7 cells 
expressing zSgreen protein, both stably transfected, were kindly provided by Dr. Hon 
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Sing Leong and Dr. Ann Chambers (Departments of Oncology, Medical Biophysics and 
Pathology, University of Western Ontario). These cells were incubated with the peptide 
library and observed under a fluorescence microscope one hour after incubation. The 
desired outcome was to observe MDA-MB-231 cells attached to a number of beads, 
which means those beads contain a bioactive sequence (Figure 4.2). 
 
 
 
 
 
 
 
Figure 4.2 Schematic of a microscope view of beads and cells showing a positive 
bead surrounded by cells. 
 
The selection of positive beads was performed manually after using a reversible 
chemical cross-linking method112,113, where the cells and beads were incubated with  4% 
formaldehyde before analysis. After the incubation, a 2M glycine solution was added to 
the wells to quench cross-linking and allow for the screening process. This procedure of 
cross-linking is known to show no interference with MALDI tandem mass spectrometry 
analysis.114 Crosslinking can be easily reverted by washing the beads extensively with 
95% ethanol.  Selected beads were analyzed by MALDI tandem mass spectrometry. Of 
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50 beads selected, 33 sequences were fully determined, giving a success rate of 66% 
(Figure 4.3). 
The presence of multiple positive hits, showing the high affinity of this library 
also raised concerns regarding the specificity of such peptides (Figure 4.4).  For that 
reason, an extra step of screening was made necessary, where positive sequences were 
resynthesized and screened in parallel with two different cell lines (MDA-MB-231 versus 
MCF-7), in a positive versus negative screening.  
Figure 4.3 Fragment assignments for one of the positive sequences obtained 
through screening of the OBOC library. Due to the presence of more than one possibility 
for a certain position, small libraries containing variations of positive peptides were built. 
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Figure 4.4 Positive beads covered with MDA-MB-231 cells in suspension after 
screening and before cross-linking. 
 
4.2.3 Positive Sequences Validation and Negative Screening 
Of all positive sequences obtained through library screening and subsequent 
MALDI tandem mass spectrometry, a total of 33 peptides were synthesized, including 
sequences determined by MALDI as well as a few sequence variations for peptides that 
did not provide a clear spectra of fragmentation or included amino acids with similar 
molecular weight such as lysine and glutamine or leucine and isoleucine. For those 33 
peptides, a second cell binding experiment was performed, where the peptides were 
incubated with both MDA-MB 231 and MCF-7 cells in parallel, in order to investigate 
their specificity to a more aggressive cell line in comparison to a less aggressive cell line. 
In order to perform this experiment, MCF-7 cells transfected with zSgreen protein were 
used (Figure 4.5). 
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Figure 4.5 Positive versus negative screening for peptides 4.8 (top) and 4.9 
(bottom). MCF-7 cells are shown in green (left), and MDA-MB-231 cells in red (right). 
 
As expected, most peptides showed remarkable binding with both cells lines, 
showing no specificity to specific breast cancer markers. Of 33 peptides analyzed, five 
peptides showed a distinction in binding when comparing MDA-MB-231 and MCF-7 
cells. Out of these five peptides there was no obvious similarities on the peptide 
sequences to allow for the study their structure activity relationship, which is due to the 
small percentage of possible sequences that were screened and also the limited size of the 
library (Figure 4.6). 
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Figure 4.6 Five gallium-peptides that showed specificity to a more aggressive 
breast cancer cell line.  
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The five peptides confirmed by this screening were synthesized for further 
evaluation and development into potential imaging agents. 
 
4.2.4 Synthesis and Characterization of Positive Peptides 
Positive peptides, after validation, were resynthesized in order to be developed 
into imaging agents. Using standard solid phase peptide synthesis and purification 
procedures, five DOTA-containing peptides were prepared and purified for radiolabeling 
using 68Ga. As it requires a longer time of reaction, the coupling step for DOTA was 
performed manually after a last Fmoc deprotection. Reagent K was used to remove the 
peptide off resin and also remove side chain protecting groups, allowing for later 
radionuclide labeling. 
The purified peptides were characterized using HPLC and mass spectrometry. 
High-resolution mass spectrometry (HRMS) spectra were obtained using electrospray 
ionization (ESI), fragmentation was confirmed by the use of MALDI tandem mass 
spectrometry and compared with spectra obtained from library screening in order to 
confirm the peptide sequences. Since the concentration of pure peptides is normally 
higher than what is obtained from a single bead, the signal obtained from the 
spectrometer is also higher than for the library beads, meaning that fragments that were 
not previously observed can be clearly seen, and differences between some sequence 
variations can be clearly spotted. 
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In order to fully characterize these compounds, coordination with non-radioactive 
gallium (69/71Ga) was performed for all five peptides. Table 4.1 shows the results of the 
[M+H] (high-resolution mass spectrometry) and purity of the desired compounds before 
and after 69/71Ga coordination (Figure 4.7). Compounds 4.1 to 4.5 correspond to the non-
gallium coordinated version of peptides 4.6 to 4.10, respectively. 
 
Table 4.1 Analysis of DOTA-peptides and [69/71Ga]DOTA-peptides. 
 
* Purity was determined by integration of the area under the curve 
 
Compound Peptide 
Calculated 
m/z 
Observed 
m/z Purity* 
    [M+2H]2+ [M+2H]2+   
4.1 DOTA-TPRGFHVK-NH2 663.8675  663.8667  >99%  
4.2 DOTA-RQSQIPIA-NH2 649.3575  649.3419   >99%  
4.3 DOTA-TPRGFHVK-NH2  663.8498 663.8340   >99%  
4.4 DOTA-ADNHPGHF-NH2 640.2948  640.2773  >99%  
4.5 DOTA-KNVRWPHN-NH2 718.3818  718.3800  >99%  
4.6 [69/71Ga]DOTA-TPRGFHVK-NH2 696.8190  696.8086   >99%  
4.7 [69/71Ga]DOTA-RQSQIPIA-NH2  682.3163 682.3066  >90%  
4.8 [69/71Ga]DOTA-TPRGFHVQ-NH2  696.8008 696.7919  >95%  
4.9 [69/71Ga]DOTA-ADNHPGHF-NH2 673.2459 673.2443  >99%  
4.10 [69/71Ga]DOTA-KNVRWPHN-NH2 751.3328 751.3275  >95%  
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Figure 4.7 A) MS spectra for compounds 4.1 (left) and 4.6 (right). B) MS spectra 
for compounds 4.2 (left) and 4.7 (right). C) MS spectra for compounds 4.3 (left) and 4.8 
(right). 
 
C) 
A) 
B) 
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4.2.5 68Ga Radiolabeling 
Radiolabeling of the five peptides was performed in HEPES buffer by heating the 
reaction vial using an Eckert and Ziegler 68Ge/68Ga generator, connected to a series of 
synthesis modules, controlled remotely by the user via a process computer (Figure 4.8). 
The interface of the program used for the radiolabeling of peptides is shown on Figure 
4.9. 
 
 
 
 
 
 
 
 
 
Figure 4.8 Eckert and Ziegler modular lab automated synthesis unit used for 68Ga 
labeling. 
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Figure 4.9 Scheme of the program used for peptide radiolabeling (Modular Lab). 
 
68Ga is eluted from the generator via a squeeze pump and approximately 3 mL of 
0.1 N HCl (vial 1-1). The eluate, containing 68Ga and other impurities, travels to a strong 
cation exchange column, which provides an initial purification step.  From this column, 
68Ga is eluted using 0.5 mL of a 0.05 N HCl in 98% acetone solution (N2 solution, vial 1-
3), and then carried to the reaction vial, which contains the peptide dissolved in HEPES 
buffer. After completion, the mixture is eluted through a C18 light Sep Pak for further 
purification. An aliquot of 2 mL of water is passed through the cartridge initially, to 
remove any free 68Ga. After this wash, the final product is eluted using EtOH into a clean 
glass vessel. An aliquot of the final product is then diluted with H2O and acetonitrile for 
HPLC analysis. 
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Peptides 4.4 and 4.5 were successfully radiolabeled with 68Ga, initially using 100 
µg of the precursor, with radiochemical yields (RCY) of 76% (4.9*) and 67% (4.10*) 
(decay-corrected) respectively, and radiopurity greater than 99%. Confirmation of 
peptide identity was done by co-injection of the radiolabeled peptide and the cold-labeled 
compound on HPLC. An HPLC comparison of radiolabeled, cold-labeled and precursors 
for all five peptides is shown on Figures 4.10, 4.11 and 4.12, which show the similar 
retention times of radiolabeled compounds when compared to the 69/71Ga-peptides and 
precursor samples. 
 
Figure 4.10 Stacked HPLC traces for peptide 4.6* showing the traces for the 
precursor (4.1) (green), cold gallium-labeled standard (4.6) (blue) and radiolabeled  
(4.6*) (yellow) products. 
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Figure 4.11 Stacked HPLC traces for peptides 4.7* (a) and 4.8* (b) showing the 
traces for the precursor (4.2, 4.3) (green), cold gallium-labeled standard (4.7, 4.8)  (blue) 
and radiolabeled (4.7*, 4.8*)  (yellow) products.  
a) 
b) 
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Figure 4.12 Stacked HPLC traces for peptides 4.9* (a) and 4.10* (b) showing the 
traces for the precursor (4.4, 4.5) (green), cold gallium-labeled standard (4.9, 4.10) (blue) 
and radiolabeled (4.9*, 4.10*)  (yellow) products.  
a) 
b) 
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The specific activity when using 100 µg of precursor was determined to be 
between 1.3-2.0 GBq/ µmol, which is lower than preferred for a targeted imaging agent. 
In order to improve these values, while preserving radiochemical yields for these 
peptides, a smaller amount of the precursor was used for radiolabeling (10 µg). Results 
obtained showed excellent radiopurity (>99%), with high radiochemical yields and 
improved effective specific activity (Table 4.2). 
 
Table 4.2 Radiochemical yield, radiopurity and specific activity for the five lead 
candidates. 
 
 
 
 
Compound  68Ga-DOTA- 68Ga-DOTA- 68Ga-DOTA- 68Ga-DOTA- 68Ga-DOTA-
KNVRWPHN-
NH2 Structure 
TPRGFHVK-
NH2 
RQSQIPIA-
NH2 
TPRGFHVQ-
NH2 
ADNHPGHF
-NH2 
Compound  
4.6* 4.7* 4.8* 4.9* 4.10* 
Number 
Precursor  
 10µg 10µg 10µg  10µg 10µg 
amount (µg) 
Specific 
Activity 
(GBq/µmol) 
13.19  12.14  5.77  6.19  17.95  
RCY (%) 
decay  82.5%  84.7%  36.1%  31.6%  86%  corrected 
(d.c.) 
Radiopurity 
(%)  >99%  >99%   >99%   >99%   >99% 
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4.3 Conclusions 
A gallium-containing OBOC octapeptide library was synthesized containing the 
chelator and metal motif on the N-terminus of the peptides. Screening of this library 
against MDA-MB-231 cells resulted in the identification of 50 positive hits, from which 
33 sequences were obtained, leading to a sixty-six percent success rate.  This satisfactory 
number once again shows that MALDI tandem mass spectrometry can be successfully 
used to determine peptide sequences that contain the [Ga]DOTA complex. 
In a search for peptide sequences that would specifically bind to a more 
aggressive cell line (MDA-MB-231), peptides containing the sequences discovered by 
MALDI tandem mass spectrometry. This “positive versus negative” screening led to 5 
peptides that showed a better binding affinity to a more aggressive cell line, instead of 
MCF-7 cells. These peptides were then chosen to be developed into imaging agents, 
which includes further characterization, radiolabeling and in vivo animal PET imaging. 
All five peptides were successfully characterized and radiolabeled using 68Ga, however, it 
would be ideal to repeat the labeling for compounds such as 4.8* and 4.9*, in order to 
obtain better radiochemical yields. 
Experiments are now being conducted for small animal PET imaging using 
tumour-bearing mice (MDA-MB-231 cells), looking for specific tumour targeting. 
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4.4 Experimental Methods 
All standard Fmoc protected amino acids and coupling agents were obtained from 
Peptides International. Fmoc-Rink amide MBHA resin (4-(2’,4’-dimethoxyphenyl-(9-
fluorenylmethoxycarbonyl)-aminomethyl)-phenoxy-acetamidonorleucyl-4-methyl 
benzhydrylamine resin) was obtained from Nova Biochem. RP-C18 Sep-Pak© cartridges 
were obtained from Waters. 68Ge-68Ga generator was obtained from Eckert and Ziegler. 
 
4.4.1 OBOC Library Synthesis 
The OBOC library was synthesized using the Biotage® Syro WaveTM Peptide 
Synthesizer. For that, eighteen natural amino acids, excluding cysteine and methionine, 
were used. Fmoc-ANP-OH (4 eq.) was manually coupled to Tentagel S NH2 resin 
(loading 0.29 mmol/g) using standard Fmoc peptide synthesis procedures. The resin was 
kept in the dark during the synthesis process due to the nature of the ANP linker. In the 
automated synthesizer, the Fmoc group was removed using a 20% piperidine in DMF 
solution (800 µL/well), twice. To every well, one different amino acid (3 eq.), HCTU (3 
eq.) and DIPEA (6 eq.) in DMF were added. After each coupling step, the resin was 
rinsed with DMF and DCM multiple times and recombined in a peptide vessel. After 
mixing it thoroughly, the resin was again divided among the seventeen vessels and placed 
back on the synthesizer for another round of Fmoc deprotection and coupling. The 
process of deprotection and coupling was then repeated until the library reached its size 
of eight amino acids. The resin was recombined, a last Fmoc deprotection was performed 
and the coupling step for the chelator was performed manually, using DOTA-
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tris(tBu)ester (4 eq.), HCTU (4 eq.) and DIPEA (4eq), under shaking, for a period of 3 
hours. 
Gallium coordination was performed by adding 1 g of GaCl3 in a round bottom 
flask containing the library in approximately 150 mL of NaOAc/HOA buffer (pH = 4). 
The mixture was left for stir at room temperature for 45 minutes and another 45 minutes 
at 75oC. The library was kept dry under -80oC until the day of usage. Small samples were 
solubilized in PBS and left at room temperature prior to library screening. 
 
4.4.2 Cell Growth 
MDA-MB-231 cells stably transfected with tdTomato protein and MCF-7 cells 
stably transfected with zSGreen protein were kindly provided by Dr. Hon Sing Leong and 
Dr. Ann Chambers. 
MDA-MB-231 cells expressing tdTomato protein were grown in Alpha 
modification of Eagle’s medium (AMEM) media supplemented with 10% fetal bovine 
serum (FBS), 1% non-essential amino acids and 1% sodium pyruvate.  
MCF-7 cells expressing zSGreen protein were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) low glucose media, supplemented with 10% FBS. 
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4.4.3 Library Screening 
MDA-MB-231 cells (approximately 500,000 cells) were added to multiple wells 
on 6-well plates with approximately 3 mL of AMEM serum-free cell culture media. To 
these wells, approximately 15,000 library beads, solubilized in 30 µL of PBS were added. 
The plates were protected from light and submitted to gentle shaking in an 
incubator, on 37o C, 85 rpm, for one hour. After one hour, cells and beads were imaged 
using the Olympus IX70 inverted fluorescent microscope prior to fixation. Fixing of the 
cells was performed using a 4% formaldehyde solution for 15 minutes. The cells were 
then washed with PBS twice before observation on a fluorescence microscope for binding 
confirmation. 
For sequence determination later on, the beads were treated rigorously with 
ethanol to remove any bound cells, and then washed several times with water. 
 
4.4.4 MALDI Tandem Mass Spectrometry 
After following the cleavage protocol (UV light, 4 hours), 2 µL of each peptide 
solution obtained, in water, was mixed with 2 µL of trans-α-cyano-4-hydroxycinnamic 
acid (CHCA) matrix for a few minutes. 0.75 µL of this mixture was spotted onto a 
MALDI target plate in duplicate for analysis. The solvent was allowed to evaporate, 
leading to a co-crystallization of the matrix and peptide. The samples were then analyzed 
utilizing MALDI tandem mass spectrometry. 
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4.4.5 Negative Screening 
MCF-7 cells (approximately 500,000) were added to multiple wells on 6-well 
plates with approximately 3 mL of serum-free low glucose DMEM cell culture media. To 
each well, different peptide beads were added, to a total of 33 wells. The same procedure 
was followed for MDA-MB-231 cells, on serum-free AMEM media. The plates were 
protected from light and submitted to gentle shaking in an incubator on 37o C, 85 rpm, for 
one hour. 
After incubation, the wells corresponding to each peptide sequence were observed 
in parallel in order to compare the binding of a more aggressive cell line versus a less 
aggressive one. For peptides that specifically bind to the cell line of interest, pictures 
were taken for a visual comparison. 
 
4.4.6 General Peptide Synthesis Procedures 
The procedure described corresponds to the synthesis of peptides 4.1, 4.2, 4.3, 4.4 
and 4.5. 
Standard Fmoc solid phase peptide synthesis (SPPS) procedures were utilized to 
obtain the desired peptides containing all side chain protecting groups. Rink amide 
MHBA NH2 resin (0.1 mmol, 0.52meq/g) containing a Fmoc protecting group was was 
swelled using DCM washes, and the Fmoc group was removed using a 20% piperidine in 
DMF solution (2x, 5 min and 20 min, respectively). The deprotection solution was 
removed from resin using a series of DMF and DCM washes. Fmoc protected amino 
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acids (0.3 mmol, 3 eq) were dissolved in approximately 0.5 mL DMF, along with HCTU 
(0.3 mmol, 3 eq) and DIPEA (0.6 mmol, 6 eq). For the peptides described above, the 
amino acids used were: Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-
His(Trt)-OH, Fmoc-Val-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ser(tBu)-OH, 
Fmoc-Ile-OH, Fmoc-Asn(Trt)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-
Asp(OtBu)-OH, Fmoc-Ala-OH and Fmoc-Gln(Trt)-OH.  The solution of coupling 
reagents plus activated amino acid was then combined with the resin and agitated for one 
hour. The resin was washed with DMF and DCM multiple times. This process of 
coupling and deprotection was then repeated until the desired sequence of the peptides 
was obtained. Kaiser test90 was performed to confirm the presence of free primary amino 
groups after deprotection and the absence after coupling of amino acids. After a last 
Fmoc deprotection, the chelator DOTA, in its tBu-protected form (tris-tBu-DOTA) was 
added manually by the use of solid phase peptide synthesis techniques (4 eq, 0.4 mmol), 
using HCTU (4 eq, 0.4 mmol) and DIPEA (8 eq, 0.8 mmol) as coupling reagents. 
  
4.4.7 Peptide Deprotection, Cleavage and Purification 
After the chelator coupling, peptides were mixed with 5 ml of a solution of 95% 
TFA, 2.5% H2O and 2.5% TIPS for six hours to remove the peptide from resin as well as 
remove side-chain protecting groups.  The resulting solution was cooled on ice and cold 
TBME (20 mL) was added to the solution until a white precipitate formed.  The peptide 
solutions were then centrifuged at 0oC at 3000 rpm for 10 minutes.  The liquid was 
decanted and the resulting pellet was mixed with cold TBME (20 mL) and subsequently 
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centrifuged again under identical conditions to obtain the crude peptide. Following the 
removal of the supernatant, the peptide pellets were dissolved in water, frozen at -78°C 
and lyophilized. Small samples of the resin were cleaved using the full deprotection 
procedure in order to monitor reaction completion. 
The crude peptides were dissolved in water, purified by HPLC (15 minutes, linear 
gradient 15% solvent A in solvent B to 70%) and identified by mass spectrometry, giving 
white powders after lyophilization. High-resolution mass spectrometry spectra were 
obtained using ESI-MS (Water Micromass Quattro MicroTM API). Refer to Table 4.1 for 
mass spectrometry data. 
 
4.4.8 69/71Ga Coordination Procedures 
The procedures here stated correspond to compounds 4.6, 4.7, 4.8, 4.9 and 4.10. 
10 mg of each DOTA-peptide (4.1, 4.2, 4.3, 4.4, 4.5), dissolved in 0.1 M pH 4 
NaOAc/HOAc buffer were added to a round bottom flask containing 5 mg of GaCl3. The 
mixture was stirred at room temperature for 30 minutes before heating to 70o C for 
another 30 minutes. The resulting mixture was purified using a light C18 RP Sep-Pak© 
cartridge. The reaction mixture was passed through the Sep-Pak©, and the cartridge was 
washed with 10 mL of water in order to remove unreacted GaCl3. Ethanol is then used to 
wash out the labeled product and subsequently removed in vacuo. The peptide products 
are isolated as white powders and characterized using HPLC and mass spectrometry. 
Refer to Table 4.1 for mass spectrometry data. 
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4.4.9 68Ga Radiolabeling 
The procedure for radiolabeling was the same for all peptides in this chapter (4.6*, 
4.7*, 4.8*, 4.9* and 4.10*). 
10 µg of the DOTA-peptide (4.1, 4.2, 4.3, 4.4, 4.5) solution (1mg/mL in pH 3.5 
HEPES buffer) was added to a clean glass microwave vessel. To this aliquot, another 700 
µL of the buffer was added in order to obtain a final solution with concentration in the 
order of µM. To this vessel, 10 mCi of 68GaCl3 was added, eluted from a 68Ge/68Ga 
generator using 3 mL of a 0.1 M HCl solution. Purification and isolation of the final 
product were achieved using a pre-activated light C18 RP Sep-Pak© cartridge, prior to 
the transfer to a clean microwave vessel (using a 0.05 N HCl in Acetone solution as 
eluent). The purity of the products was analyzed using analytical RP-HPLC (SunfireTM 
RP-C18 column 4.6 x 150 mm, 5um) coupled to a gamma detector. The system employed 
a Waters 1525 Binary HPLC pump, Waters 2487 dual λ absorbance detector, Waters In-
Line degasser and Breeze Software (version 3.30). 
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Chapter 5: Conclusions 
The advent of molecular imaging led to an increasing search for new potential 
biological targets and the study of new and optimized ways of incorporating 
radionuclides into imaging agents. Furthermore, it also resulted in more detailed studies 
on radioisotopes, in order to improve its production, accessibility, radiochemical yields 
and specific activity. For this matter, more recently, 68Ga is been explored as a PET 
imaging agent, as it has a very suitable half-life, can be easily obtained from a 68Ge/68Ga 
generator and its chelation chemistry is well understood, especially when using 
bifunctional chelators such as DOTA and NOTA. 
In the present research, we are able to offer enough proof that OBOC 
combinatorial libraries containing the [Ga]DOTA surrogate prior to screening are able to 
provide positive hits that can be further developed into imaging agents. The library 
designed showed great stability under synthesis and screening conditions and positive 
hits obtained can be easily developed into potential imaging agents.  
The aim of this research was to prove the ability of not only synthesizing such a 
library, but also being able to screen for a biological target and obtain the positively 
interacting peptide sequences using MALDI tandem mass spectrometry. After 
confirmation of the ability of sequencing [Ga]DOTA-containing peptides, a breast cancer 
cell line was chosen for the screening of the library. 
Although one of the goals for this study was to be able to randomize the position 
of the radionuclide with the chelator, due to the changes in the fragmentation pattern for 
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the peptides, it would increase the challenge of determining the sequences of positive 
peptides. Therefore, a library containing the imaging entity on the N-terminus was 
synthesized. In order to look at the different possibilities for the position of such an 
entity, further studies are needed in order to understand the fragmentation of peptides 
containing the [Ga]DOTA complex in different positions within peptide chain and how 
those changes would affect the peptide conformation on the bead and consequently cell 
binding. 
The OBOC library synthesized contains between 1 to 2 million unique peptide 
sequences, which contained all of the natural amino acids, excluding cysteine and 
methionine, and was screened against MDA-MB-231 cells, an aggressive breast cancer 
cell line. For this study, a target was not yet identified, as the search was for positive 
peptides that would only bind to the cell line of interest. To confirm specificity, positive 
sequences obtained, and its variants, were resynthesized and screened against MCF-7 
cells in parallel with MDA-MB-231 cells, and peptides that specifically bound to MDA- 
MB-231 cells were selected for further characterization. Since there is no previous 
knowledge on the target and also the five peptides that show a positive interaction have 
different sequences, it is difficult to comment on structure-activity relationship. 
One of the main advantages of OBOC libraries is the ability of incorporating 
unnatural amino acids115,116 and non-peptide structures, such as chelators and 
radionuclides, and when using MALDI tandem mass spectrometry as the sequence 
determination method, those structures can be easily accounted for. It is known that 
unnatural amino acids or non-peptides structures show a better in vivo stability, and 
further studies on sequences obtained by the screening of this library include the 
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substitution of natural amino acids by unnatural amino acids or non-peptide structures in 
order to search for better specificity and stability. 
The fact that the library already contains the imaging entity prior to screening 
represents an advantage, as it might overcome the present problems with the development 
of new imaging probes. The imaging entity corresponds to a very significant part of the 
agent, and it will most likely affect the characteristics of a targeting entity, changing its 
binding affinity and specificity. 
In conclusion, a novel gallium-containing OBOC peptide library was synthesized 
utilizing standard solid phase peptide synthesis approaches. MALDI tandem mass 
spectrometry was proved to be a useful technique for the identification of positive peptide 
sequences obtained through screening of this library with a breast cancer cell line, MDA-
MB-231.  
A study was previously reported in our lab using rhenium-containing libraries88, 
and by showing the same approach using a different radionuclide, we believe that this 
technique can be applied to other radionuclide surrogates, with proper investigation of its 
fragmentation patterns and chelate stability under synthesis and screening conditions. 
This approach for the development of new imaging probes has the potential to make the 
process of discovering new agents faster and more economically feasible. 
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APPENDIX I – CHAPTER 2 
 
HPLC TRACES 
 
HPLC trace for 2.2 
 
HPLC trace for 2.3 
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HPLC trace for 2.4 
 
HPLC trace for 2.5 
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HPLC trace for 2.6 
 
HPLC trace for 2.7 
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HPLC trace for 2.8 
 
HPLC trace for 2.9 
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APPENDIX II – CHAPTER 4 
HPLC TRACES 
HPLC trace for 4.1 
 
HPLC trace for 4.2 
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HPLC trace for 4.3 
 
HPLC trace for 4.4 
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HPLC trace for 4.5 
 
HPLC trace for 4.6 
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HPLC trace for 4.7 
 
HPLC trace for 4.8 
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HPLC trace for 4.9 
 
HPLC trace for 4.10 
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MALDI TANDEM MASS SPECTROMETRY 
 
MS Spectrum for 4.6 
MS Spectrum for 4.7 
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MS Spectrum for 4.8 
 
 
 
 
MS Spectrum for 4.9 
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MS Spectrum for 4.10 
 
MSMS Spectrum for 4.6 
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MSMS Spectrum for 4.7 
 
MSMS Spectrum for 4.8 
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MSMS Spectrum for 4.9 
 
 
MSMS Spectrum for 4.10 
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HIGH-RESOLUTION MASS SPECTROMETRY 
 
Compound 4.1  
 
 
 
 
 
 
 
 
 
Compound 4.2  
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Compound 4.3  
 
 
 
 
 
 
 
 
 
 
Compound 4.4  
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Compound 4.5  
 
 
 
 
 
 
 
 
 
Compound 4.6 
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Compound 4.7 
 
 
 
 
 
 
 
 
 
 
Compound 4.8 
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Compound 4.9 
 
 
 
 
 
 
 
 
 
 
Compound 4.10 
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68Ga RADIOLABELING 
Black: satin; Blue: UV 254 nm; Red: UV 220 nm. 
Co-injection of radiolabeled compound 4.6* with its cold labeled form 4.6.  
 
Co-injection of radiolabeled compound 4.7* with its cold labeled form 4.7 
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Co-injection of radiolabeled compound 4.8* with its cold labeled form 4.8 
Co-injection of radiolabeled compound 4.9* with its cold labeled form 4.9 
Co-injection of radiolabeled compound 4.10* with its cold labeled form 4.10 
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